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Smith-Magenis syndrome (SMS) is a complex mental retardation syndrome 
caused by deletion of 17p11.2 region or mutation of the RAI1 gene (retinoic acid induced 
1).  Individuals with SMS typically exhibit speech and motor delays, mental retardation, 
characteristic craniofacial and skeletal anomalies, and a distinct neurobehavioral 
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phenotype that includes sleep disturbances, stereotypes, and maladaptive and self-
injurious behaviors.  RAI1 is thought to be a transcription factor modulating the 
expression of genes involved in a variety of cellular functions.  Previous studies have 
shown the RAI1 gene being induced by retinoic acid (RA), a derivative of vitamin A.  RA 
plays a significant role in many processes such as immune function, neurogenesis and 
reproduction, and deprivation of RA causes craniofacial defects.  We hypothesized that 
RA could be inducing RAI1 which then acts as a transcription factor in modulating the 
expression of multiple genes.  To understand the consequences of clinical variation of 
RAI1 gene, we performed mutation screening and identified the first case of SMS without 
mental retardation.  Using a zebrafish model, full-length rai1 gene was cloned and spatial 
and temporal expression of rai1 by in-situ hybridization was evaluated and the effect of 
RA on rai1 expression was subsequently analyzed.  The data show rai1 expression in 
forebrain (diencephalon) and midbrain. A rai1 antisense morpholino will eventually be 
created to perform knockdown studies and rescue experiments.  These studies will help in 
determining the significance of the rai1 gene, and its interacting molecular pathways 
responsible for growth, development, and behavior. 
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CHAPTER 1: Introduction 
 
 
Smith-Magenis syndrome 
Smith-Magenis syndrome (SMS, OMIM #182290) is a multiple congenital 
anomalies and mental retardation syndrome caused by an interstitial deletion of 
chromosome 17p11.2 including the retinoic acid induced 1 (RAI1) gene, or mutation of 
RAI1.  Patients are diagnosed with SMS by their typical characteristics such as mental 
retardation, sleep disturbance, craniofacial and skeletal abnormalities, neurological and 
behavioral abnormalities, and ocular and otolaryngological abnormalities.  
Approximately 90% of cases have a fluorescent in situ hybridization (FISH) detectable 
17p11.2 microdeletion ranging from ~1.5 to 9 Mb, while the remaining 10% have a 
mutation in RAI1.  Almost all cases are sporadic.  The incidence rate of this 
neurodevelopmental disorder is estimated to be 1:15,000-25,000 births, but it seems 
likely that these figures represent an underestimate (10). 
Craniofacial/ Skeletal abnormalities 
SMS patients exhibit distinctive craniofacial and skeletal anomalies that include 
brachycephaly, a broad square-shaped face, midface hypoplasia, synophrys, upslanting 
palpebral fissures, deep set eyes, everted upper lip with tented appearance, micrognathia 
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in infancy, relative prognathism with age (1), brachydactyly, short stature and scoliosis. 
Short stature (< 5
th
 percentile) is observed in SMS patients during their childhood but 
with time, most individuals reach 10
th
-25
th
 percentile during adulthood (10, 15).  Other 
skeletal abnormalities include 5
th
 finger clinodactyly, 2-3 toe syndactyly, polydactyly and 
vertebral anomalies. (22, 29, 43) 
Neurological/ Behavioral abnormalities 
All individuals with SMS show hypotonia in infancy and childhood, motor and 
speech delay, and ultimately some degree of mental retardation (usually in the mild to 
moderate range).  The behavioral phenotype is also very characteristic and includes 
twirling objects, hand-wriggling, hyperactivity, attention-seeking, temper tantrums, 
outbursts, aggression ( 7, 41) and self-injurious behaviors such as self-biting, 
polyembolokoilamania (insertion of foreign objects into body orifices), onychotillomia 
(pulling out fingernails and toenails), skin-picking, finger-chewing and head-banging 
(10).  Specific stereotypes of the syndrome are the spasmodic upper body squeeze or 
―self-hugging‖ and the ―lick and flip‖ behavior that is hand-licking and page-flipping (7, 
12).  Moreover, one of the most telling clinical features is the presence of sleep 
disturbances with inverted circadian rhythm of melatonin (36).  The sleep problems 
experienced by SMS patients include difficulties falling and staying asleep, early 
awakenings, excessive daytime sleepiness, daytime napping, snoring, bed-wetting, and 
diminished rapid eye movement (REM) sleep (8, 20, 36). 
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Ocular/ Otolaryngological abnormalities 
Ocular abnormalities such as strabismus, myopia, microcornea, iris abnormalities 
are observed in SMS patients.  Along with these, otolaryngological abnormalities that 
include hearing loss, hoarse deep voice, chronic ear infections and vocal cord nodules 
and polyps are also quite common (10, 22).  Abnormalities such as hearing loss, which 
varies from being mild to moderate, could be a result of the ear infections seen in these 
patients (21, 22). 
Systemic defects and other manifestations 
 Other features noted in SMS patients include cardiovascular anomalies, renal 
abnormalities, pes-planus (flat feet), hypercholesterolemia, immunoglobin deficiencies 
(IgA, IgG and IgE), and dental abnormalities (8, 10, 22).  Cardiovascular anomalies seen 
in 30% of the SMS patients include ventricular and atrial septal defect, mild stenosis, 
tricuspid stenosis, aortic stenosis, pulmonary stenosis, tricuspid and mild regurgitation, 
mitral valve prolapse, tetrology of Fallot, and total anomalous pulmonary venous return 
(8, 11).  SMS patients also reported with renal abnormalities such as enlarged kidneys, 
duplication of the collecting duct, ectopic kidneys, kidney stones and urinary tract 
infections (8, 22).  These individuals have been reported to have dental abnormalities 
such as taurodontism and tooth agenesis (45).  
Retinoic acid induced 1 
Role of the RAI1 gene 
RAI1 (Genbank AY172136; OMIM*607642) maps to the central portion of the 
17p11.2 region, which is defined as the SMS critical region (Fig. 1).  The RAI1 gene is   
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Fig.1 Schematic of chromosome 17.  Map of the SMS critical region, including the 
RAI1 gene. Deletion of the 17p11.2 region or mutation of the RAI1 gene causes Smith-
Magenis syndrome.
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Fig.2 Genomic and protein structure of RAI1.  (a) The genomic structure of the RAI1 
gene which consists of 6 exons, of which 3-6 are coding exons.  RAI1 gene is composed 
of ~5721 bp.  (b) The protein structure of RAI1 composed of 1906 amino acids and 
includes a polyglutamine (Poly-Q), polyserine (Poly-S), a bipartite nuclear localization 
signal (NLS), and C-terminal plant homeodomain (PHD). 
 
Source: Elsea and Girirajan 2008 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  
(a) 
(b) 
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made up of 6 exons, of which 3-6 are coding exons (Fig. 2).  The RAI1 gene generates 
~7.6 kb mRNA and encodes a 1906 amino acid protein with a molecular weight of 203 
kDa (Fig. 2).  This gene was first identified in mouse pluripotent embryonic carcinoma 
cells (P19).  These cells were treated with retinoic acid (RA) which lead to neuronal 
differentiation and also induced the upregulation of the Rai1 gene (26).  The alignment of 
the human RAI1 gene sequence with other mammalian species showed the highly 
conserved nature of this gene (15).  Comparing human with mouse indicated RAI1 to be a 
homologue of the mouse Rai1, sharing 84% identity which suggests that human RAI1 
could be induced by RA in similar fashion and this induction contributes towards the 
neuronal development seen in SMS. 
Furthermore, this gene contains a polyadenylation signal and a large 3‘- UTR.  
The RAI1 protein contains a bipartite nuclear localization signal, polyglutamine and 
polyserine tracts and a plant homeodomain (PHD)/ zinc finger domain at the C-terminus 
(10, 46) (Fig. 2).  The polyserine tract at the carboxy terminal is composed of [S]3A[S]8 
and is similar to the motifs found in DRPLA and Drosophila hairless genes (10).  These 
motifs have been shown to be involved in development of the nervous system and also in 
transcription of genes (32, 39).  The PHD domain of the RAI1 protein is also similar to 
the trithorax family of the nuclear proteins which is involved in chromatin remodeling 
and regulating transcription.  In addition to this, the amino acid sequence motifs such as 
bipartite nuclear localization signal and PHD domain are found to be related to the 
transcription factor stromelysin-1 platelet derived growth-factor-responsive element 
binding protein (TCF20) (10, 39).  This suggests that RA could be inducing the RAI1 
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gene which then acts as a transcription factor in modulating the expression of genes 
involved in a variety of cellular functions (2). 
 
Retinoic acid  
Retinoic acid (RA) is a derivative of vitamin A and plays an important role in 
cellular growth, differentiation, embryogenesis, vision, immune function and 
reproduction (30, 38).  Plants and microorganisms synthesize and store carotenoids, a 
precursor of vitamin A.  Animals obtain these precursors by the intake of plants and 
convert them into retinal using retinol dehydrogenases, and then oxidize retinal into RA 
irreversibly using retinal dehydrogenases (Raldh) (6). 
These RA molecules bind to the transcription factors/receptors known as retinoic 
acid receptors (RARs) as they are not capable of binding directly to the gene (38).  The 
receptors then become activated by the binding of all-trans retinoic acid and this 
RA/RAR complex regulate gene expression by binding to short DNA sequences 
(enhancer elements) in the vicinity of the target gene (13, 33, 35).  This hypothesis was 
illustrated in an experiment done by Imai et al. in 1995, where the Rai1 gene was induced 
in P19 mouse cells upon RA treatment.  The upregulation of the Rai1 gene and 
differentiation of neurons in mice by the induction of RA suggests that RA could be 
playing an indirect role in causing neurological features seen in SMS.  
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CHAPTER 2: RAI1 variations in SMS patients and refinement 
of sequencing methodology 
 
 
Introduction 
Smith-Magenis syndrome was diagnosed in a patient for the first time by Ann 
Smith and Ellen Magenis in 1986 (43).  This syndrome is caused by an interstitial 
deletion of 17p11.2 region or a mutation in the RAI1 gene.  The deletion was identified 
using a standard cytogenetic Giemsa staining (G-banding) technique.  Although with 
time, techniques such as fluorescent in-situ hybridization (FISH) came into practice 
which made the identification of this deletion possible.  With this technique, it was 
possible to map the deletions of various sizes on the 17p11.2 region and delineate the 
SMS critical region.  The size of the deletions seen in SMS patient varies from ~1.5 Mb 
to ~9 Mb (48).  Approximately, 75% of these patients have a common deletion of ~ 3.7 
Mb.  The remaining patients have smaller or larger deletions.  The SMS critical region 
was further delineated to ~650 kb (47) that contained about 25 genes, including RAI1.  
Along with this cohort of patients with a detectable 17p11.2 deletion analyzed by 
FISH, there were a few patients that were negative for the deletion but exhibited SMS 
phenotype.  In 1995, Imai et al. had shown upregulation of the Rai1 gene (GT2) and 
differentiation of neurons by the induction of RA, suggesting that the absence of RA 
   
9 
 
could be a cause of suppression of the RAI1 gene and the neurological features seen in 
SMS.  As the RAI1 gene lies in the SMS critical region, it was hypothesized that a 
deleterious change of nucleotide in this gene could result in SMS. Several patients with 
no 17p11.2 deletion but with SMS features were identified in Slager et al. (2003), Bi et 
al. (2004), Bi et al. (2006), Girirajan et al. (2005) and Girirajan et al. (2006), Lily 
Truong. (2008),  GeneDx, and in the present report (Table 1).  These patients were then 
analyzed by sequencing the RAI1 gene to detect the variations as compared to the normal 
RAI1 sequence.  Sequence alignment identified point mutations in all of these patients.  
RAI1 mutations are usually de novo as they are not present in the parental samples.  If the 
mutations identified in SMS individuals are also present in their parents, then they are 
considered to be familial changes.  Seven cases of familial changes have been previously 
identified (Table 2).  Although the SMS individuals have inherited the changes 
maternally or paternally, there is no expressivity of SMS symptoms in their 
mother/father.  We are unsure if these nucleotide changes are a result of reduced 
penetrance, mosaicism present in the parents, or a mutation in another locus that could be 
contributing in causing SMS.  Hence, further functional studies are required to address 
these questions.  
All the mutations identified until now are located on exon 3 of the RAI1 gene.  
This exon is the largest exon in this gene and encodes > 98% of the RAI1 protein (Fig. 
2a).  Any point mutation or microdeletion in RAI1 gene usually results in a frameshift 
mutation which produces a truncated and non-functional protein, which is probably 
degraded by a post-transcriptional process called nonsense mediated decay.  This reveals  
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Table 1.  Summary of mutations in the RAI1 gene. 
 
Nucleotide 
Change 
          Amino Acid Change Remarks 
c.253del19 p.Leu85fsX60 Deletion/frameshift 
c.1119delC p.Ser373fsX65 Deletion/frameshift 
c.1449delC p.Pro483fsX34  Deletion/frameshift 
c.1974G>A p.Trp658X Nonsense mutation 
c.2773del29 p.Val925fsX8 Deletion/frameshift 
c.2878C>T p.Arg960X Nonsense mutation 
c.3103insC p.Gln1035fsX30  Insertion/frameshift 
c.3103insC p.Gln1035fsX30  Insertion/frameshift 
c.3103delC p.Gln1035fsX28 Deletion/frameshift 
c.3103delC p.Gln1035fsX28 Deletion/frameshift 
c.2966delAAGA p.Lys989fsX38 Deletion/frameshift 
c.3634A>G p.Ser1212Gly Missense mutation 
c.3801delC p.Pro1267fsX46  Deletion/frameshift 
c.4649delC p.Ser1550fsX36  Deletion/frameshift 
c.4685A>G 
c.4813A>T 
p.Gln1562Arg                                   
p.Arg1604X 
Missense mutation 
Nonsense mutation 
c.4933delGCCG p.Ala1645fsX35  Deletion/frameshift 
c.5423G>A p.Ser1808Asn Missense mutation 
c.5265delC p.Pro1755fsX74  Deletion/frameshift 
c.5280C>T p.Arg1604X  Nonsense mutation 
 
 
 
 
 
   
11 
 
 
 
 
 
 
 
 
Table 2.  Summary of familial changes in the RAI1 gene. 
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the importance of the functional RAI1 gene and its potential dosage dependent effect that 
could result in SMS features. 
 
Materials and methods 
Patient ascertainment and samples 
Twelve patients exhibiting SMS phenotypes were referred through geneticists 
from various parts of the world and their DNA/blood/saliva samples were sent to Dr. 
Sarah Elsea‘s laboratory for research purposes.  The Institutional Review Board of the 
Virginia Commonwealth University approved this study.  Informed consent for genetic 
testing was obtained from the patient and from the patient‘s parents.  A clinical survey 
was also requested that covered clinical and physical examination results such as 
individual‘s height, weight, head circumference, ENT reports, spine X-ray, podoscope of 
hands and feet, immunological tests, echocardiography, and renal ultrasound.  Most of 
the information regarding the behavioral features was obtained from the parental survey 
while the clinical information was based on the geneticist reports.  Short stature was 
measured relative to their parents or siblings height.  If their height measurement was less 
than 5
th
 percentile, then the SMS individual was considered to have a short stature.  The 
algorithm followed for the diagnosis of SMS is illustrated in Fig. 3. 
DNA isolation from whole blood 
Genomic DNA was extracted from peripheral blood samples using the DNA 
mini-kit by Qiagen (Valencia, California, USA).  The isolated DNA was quantified by a 
spectrophotometer at the absorbance ratio of 260/280. 
 13 
 
 
 
Fig. 3.  Algorithm used for the diagnosis of SMS.  A flow chart illustrating the procedure used for the diagnosis of SMS. 
Patients with clinical suspicion of SMS were evaluated for 17p11.2 deletions. Non-deletion cases were referred for RAI1 
mutation screening and if mutations were identified, their parental samples were evaluated to define the mutation as de novo or 
familial.
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DNA isolation from saliva 
 Genomic DNA was isolated from patient saliva samples using the protocol for 
manual purification of DNA from saliva by Oragene
®
.
  
The isolated DNA was measured 
by a spectrophotometer at the absorbance ratio of 260/280. 
Polymerase chain reaction 
 Polymerase chain reaction (PCR) was carried out on patient DNA by using 
overlapping primers, spanning exons 3-6 of the RAI1 coding region, as shown in Table 3. 
PCR reactions contained the following:  1X PCR buffer (50 mM KCl, 10 mM Tris-HCl 
and 1.5 mM MgCl2), 20 pmol of each forward and reverse primers (Table 3), 200 µM 
dNTPs, 1 U of Taq DNA polymerase, and 50 ng genomic DNA in a total reaction volume 
of 25 μl.  Cycling conditions were as follows:  initiation at 94°C, 5 min, followed by 35 
cycles of denaturing at 94°C, 1 min, annealing at 55-66°C, 1 min (Table 3), and extension 
at 72°C, 1 min, followed by a final elongation step at 72°C for 10 min.  PCR products 
were run on a 1% agarose gel to assess quality.  PCR products were either purified by gel 
extraction using the Qiagen Gel Extraction kit (Qiagen Inc, Valencia, California, USA) or 
by digesting with 2 U of shrimp alkaline phosphatase (SAP) and 10 U of exonuclease I 
(Exo) for a combined 7 μl reaction volume (USB Corporation, Cleveland, Ohio, USA) at 
37°C for 30 min, followed by an 80°C incubation for 15 min to inactivate ExoSAP-IT.   
Sequencing 
 DNA sequencing of these products was performed at the Virginia Commonwealth 
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Table 3.  PCR primers for RAI1 sequencing.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             
*Primers cover the coding region of RAI1 isoform a.
 
 +
Amplification requires Invitrogen® PCR enhancer. 
   PCR, polymerase chain reaction; Ann. temp., annealing temperature; UTR, untranslated region.
Exon Forward primer Reverse primer 
Product 
size (bp) 
Ann. 
temp. 
Start E3 
SHE323: 
TCTGAGGCAAAAGGAAGTGG 
SHE324: 
GACTGGGAATGCTGAGGAAA 
770 62ºC 
3 
SHE505: 
CCCGAGTCATGCAGTCTTTT 
SHE506: 
TGGTAATGGAGGGTTTCCTG 
925 60ºC 
3 
SHE507: 
GGTCCAGAATCTTCATGCCTA 
SHE508: 
CATGTCGTCAGGAGAGGTCA 
947 62ºC 
3 
SHE509: 
CTGCCAGGGTCAACAGCAAC 
SHE510: 
CTCCTCCTCAGCTTCCAGGT 
995 64ºC 
3 
SHE511: 
AGGAGGACCTGGAAGCTGAG 
SHE512: 
GTGACCGAAGGATCATGGAG 
861 66ºC 
3 
SHE513: 
GCTCCAAGACCAAGGAGACA 
SHE514: 
GCCTCGGTTTTGAAACAGTCA 
910 62ºC 
3 
SHE515: 
GGCCTCTCCTGGTAATCCTC 
SHE516: 
GCAGCAAACAAGGCAAGAGGT 
1010 64ºC 
3 
SHE335: 
AAACCGAGGCCTTCACATC 
SHE336: 
CACACTCGGGACCTTTGAGT 
964 60ºC 
end E3 
SHE339: 
CTACCCTGAACACTGCCTCC 
SHE340: 
AGAGGCAATGGAGACAGGAA 
887 60ºC 
4 
SHE527: 
CCAGCCTGTAAAGCTTGAGG 
SHE528: 
GGAATGCCTCATTTCCATGT 
362 62ºC 
5 
RA46: 
GGAGTGGAGTGGAGTGTGGAGG 
RA45: 
GGACTGTGAAGGAGGTGCGAG 
310 64ºC 
6+3'UTR 
SHE345: 
ACTGTGAAGTCCGAGGTCGT 
SHE346: 
GACTGGAAAGGGGACAAACA 
766 62ºC+ 
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University Sequencing Core by cycle sequencing.  Purified PCR product (10 ng/μl), 20 
ng/μl of each primer, and 4 μl of the ABI Prism terminator cycle sequencing ready 
reaction mix (Applied Biosystems, Foster City, California, USA) were combined in 10 μl 
final volume for 25 cycles.  The samples were then cleaned with filter paper, resuspended 
in formamide, denatured at 95°C for 2 min, and loaded onto an ABI3730 genetic analyzer 
(Applied Biotech/Hitachi).  
Sequence alignment and analysis 
The chromatogram results were received from the sequencing core and analyzed 
by comparing patient sequencing results with the normal RAI1 sequence visually by 
looking for heterozygosity and sequence quality and also by aligning the patient sequence 
with the RAI1 mRNA database sequence at the NCBI and Genome Browser using Clustal 
X and Bioedit.  Forward and reverse primer sequencing results were used to confirm the 
presence of any variation identified in the patient.  Parental samples were evaluated for 
any identified mutation.  
 
Results 
Clinical and molecular features of patients with RAI1 variations 
 Twelve patients with negative FISH results for 17p11.2 deletion were tested for 
RAI1 variations such as SNPs and mutations by sequencing of the RAI1 gene.  Most of 
them were identified with SNPs that were known and listed in the database.  Four of 
these patients were identified with novel SNPs, and two of these SNPs were located in 
the intronic region and are of unknown significance (Table 4).  These polymorphisms 
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have been identified in at least 1% of the normal population and are considered to be non-
disease causing.  However, we are unaware of their potential effect on SMS phenotype 
and hence, further studies have to be performed to study their role in SMS.  Besides the 
identification of novel SNPs, we also identified the first SMS patient with an RAI1 gene 
mutation that does not show frank mental retardation.  Detailed molecular and clinical 
information of these patients are mentioned below. 
 
Table 4.  Novel RAI1 mutations and polymorphisms identified in present study. 
 
Patient 
 
 
Novel 
Mutation 
 
Amino acid 
change 
 
Novel 
SNPs 
 
Amino acid 
change 
SMS339 c.2966delAAGA p.Lys989fsX38 c.2773C>A p.Val925Ile 
SMS349   c.3357C>T p.Ser1119Ser 
SMS346   c.5710-
22G>T 
N/A 
SMS351   c.5710-
49C>T 
N/A 
 
SMS331 
 SMS331 is a 7 year old male of African American descent and had been evaluated 
since he was 17 months old.  He exhibited SMS features such as sleep disturbance, 
mental retardation, speech delay, development delay, hypotonia, broad nasal bridge, 
upturned nose, tented upper lip, strabismus, vision impairment and chronic ear infections.  
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His self-injurious behavior included head-banging, face-slapping and self-biting.  At age 
of 17 months, his weight was 21.3 kg and height was 113.2 cm, which is ~ 75
th
 percentile 
of weight/height scale.  
Laboratory findings show normal karyotype (46 XY), negative fragile X studies, 
normal FISH for del(17)( p11.2) and normal aCGH. RAI1 sequencing identified four 
polymorphisms, three of them were in heterozygous state and all of them were reported 
in the SNP database (Table 5).  These nucleotide changes were not deleterious and 
therefore, non-disease causing mutations.  No other abnormalities in the RAI1 gene were 
identified in this patient.  
SMS332 
SMS332 is 11 year old Caucasian female with a history of cognitive impairment, 
behavioral problems, and seizures.  She was born at 37 weeks gestation by vaginal 
delivery with a birth weight of 5 pounds; 10 ounces (25
th
- 50
th
 percentile), a birth length 
of 19 inches (50
th
 – 75th percentile), and a head circumference of 12.5 inches (10th- 25th 
percentile).  She had suffered from jaundice after birth. Her behavioral problems included 
polyembolokoilomania, repetitive movements, food obsession and sleep disturbances.  
She also exhibited other features consistent with SMS such as midface hypoplasia, a 
broad, square face, tented upper lip, mental retardation, speech and motor delay. 
 Her family history was quite complicated.  She had two brothers and the older 
one was diagnosed with pervasive developmental disorder.  The patient‘s mother had a 
sister whose son was diagnosed with Down syndrome.  Her grandmother committed  
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Table 5.  Known polymorphisms identified in present study. 
         Poly Q 
 c.269G>C c.493C>A c.837G>A c.1992G>A c.4311T>C c.4530C>T c.5334G>A c.5601T>C Allele  
1 
Allele  
2 
SMS331    2  1  1   1 14 14 
SMS332 1 1  1 1   1  1  13 14 
SMS336 1    2  1  1 1   13 14 
SMS339 2 2  2      13 13 
SMS343        2  14 14 
SMS344 1  1  2      10 13 
SMS345    2     2  14 14 
SMS346    2    2 14 14 
SMS348 1  1  1  1     1  13 14 
SMS349    2  1  1   1  12 13 
SMS351    1    2 14 14 
SMS356 1  1  1 1     1  13 13 
1 – SNPs present in the heterozygous state 
2 – SNPs present in the homozygous state 
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suicide and had a history of depression. Her maternal aunt was reported with myasthenia 
gravis.  The patient‘s maternal grandfather had 2 brothers who died from heart problems.  
Her father‘s sister died of diabetes and renal failure.  Her paternal uncle had a son with 
autism.  
Laboratory data included normal female karyotype, normal FISH for 
del(17)(p11.2), normal aCGH and negative result for Prader-Willi and Angelman 
syndrome (tested by methylation specific PCR for SNRPN gene).  Mutation screening 
analysis identified six polymorphisms in SMS332, and all of them were in heterozygous 
state (Table 5).  No other RAI1 variations were identified in this patient‘s sequencing 
results. 
SMS336 
 SMS336 is 5 year old female of Caucasian descent.  She was evaluated at 3.5 
years of age due to her unusual growth delay features.  She was born at 37 weeks via 
normal spontaneous vaginal delivery to her 21 year old G1Po mother.  During pregnancy, 
her mother had suffered from frequent UTIs, hypertension, group B strep and decreased 
movement towards the end of pregnancy.  Patient had experienced multiple episodes of 
otitis media which affected her hearing, and she required the placement of bilateral 
myringotomy tubes.  She exhibited some SMS features such as sleep disturbances, 
aggressiveness, language delay, temper tantrums, licking her hands, and 
polyembolokoilomania.  At age 3, height (35.4 inches) and weight (28 pounds) were 
below the 5
th
 percentile.  Her physical features included frontal bossing of the forehead, 
up-slanted eyes and up-turned nose. 
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Laboratory data included a normal karyotype.  RAI1 sequencing identified five 
polymorphisms, and four of them were in heterozygous state (Table 5).  Additional 
aCGH studies revealed a duplication of 4p16.1 region. 
SMS339 
SMS339, referred for genetic evaluation at 14 years of age, is a female of 
Caucasian descent (both parents originate from South Italy) (Fig. 4 and 5).  She was the 
second child of healthy non-consanguineous parents, and she had a healthy female 
sibling.  Her parents had experienced three episodes of spontaneous abortion, all during 
the 1
st
 trimester of gestation.  Due to the history of recurrent miscarriages, karyotype 
analysis was performed on her parents, and results were normal.  The family history was 
otherwise unremarkable.   
The patient was born at term by normal vaginal delivery.  Birth weight was 3,660 
g (75
th
 centile), length 50.5 cm (25-50
th
 centile) and OFC 35 cm (50
th
 centile).  Apgar 
scores were 8 at 1 min and 9 at 5 mins.  She had mild hypotonia during neonatal period 
and early infancy but showed normal motor development.  Daytime continence was 
achieved at 5 years, and nocturnal enuresis persisted until the age of 6.  The patient 
suffered from recurrent episodes of acute otitis media until 6 years of age, when a 
tonsillectomy was performed.  At age 7 years, an audiometric evaluation excluded the 
presence of hearing loss.  At age 10 years, an episode characterized by jerking 
movements of the upper and lower extremities was interpreted as febrile convulsions.  
The body temperature was 39°C, and subsequent EEG tests showed no abnormalities.  At 
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the age of 11 years, she underwent orthodontic treatment to resolve dental crowding.  She 
attained menarche at 13 years with regular periods since then.  
Evaluation at age 14 years revealed a broad face, bushy eyebrows with mild 
synophrys, upslanting palpebral fissures, full-tipped nose, mild retrognathia, hoarse 
voice, dry skin, overeating and mildly overweight (body mass index = 25.9), tricuspid 
regurgitation, and a history of constipation and recurrent urinary tract infections.  Her 
body weight fell between 75
th
 and 90
th
 centile (62.5 kg), height between 10
th
 and 25
th
 
centile (155.4 cm), and head circumference was at +1.2 standard deviations (55.8 cm).  
Fig. 4 shows her SMS features observed since childhood, and Fig. 5 (A-D) shows whole 
body pictures and the facial appearance of the patient at age 14 years.  Skeletal anomalies 
included brachydactyly of fingers and especially toes, proximal cutaneous syndactyly of 
toes 2-3 (Fig. 6A-C), pes planus (Fig. 6D), and dorsolumbar scoliosis (Fig. 6E).  Scoliosis 
was diagnosed at 8 years of age and became more severe over time.  The compliance of 
the patient with the physiotherapy was very low, and she firmly refused to wear the 
orthopedic brace.   
The patient had been evaluated by psychologists on several occasions using the 
Wechsler Intelligence Scale for Children (WISC-R).  At 10 years, 9 months of age, her 
IQ was 82, while at 11 years, 8 months of age, the IQ was 78.  No differences in verbal or 
performance IQ were noted.  However, a repeat examination at 11 years, 10 months 
revealed a total IQ of 91, with verbal IQ at 100 and performance IQ at 84.  At the present 
age of 17 years, the patient was again evaluated by the WISC-R and had a total IQ score 
of 76 with no differences in verbal or performance IQ; however, the psychologist noted 
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significantly reduced motivation and collaboration in this examination with concerns that 
the test results did not support her true abilities.  Despite some learning disabilities, a 
certain weakness in sequential processing, and poor short-term memory, she was able to 
attend school until the age of 12 years without the help of dedicated persons.  Other 
neurobehavioral features included weak relational and social skills, tendency to depressed 
mood, obsessive thinking, stereotypies, and maladaptive and self-injurious behaviors, 
which worsened with age (especially since the onset of puberty).  The obsessive thinking 
consisted of constant fear to die, to be abandoned, and to have been adopted.  The 
maladaptive behaviors included temper tantrums, disobedience, impulsivity, verbal 
aggressiveness, attention-seeking, and prolonged crying.  She showed self-abusive 
behaviors such as skin-picking of the legs, nail-yanking, self-hugging, 
polyembolokoilamania, cutting locks of her own hair, tearing away her eyebrows, writing 
or painting the skin, mouthing of hands and objects, and grinding of the teeth.  Moreover, 
the patient had significant sleep disturbance, which consisted of difficulties falling asleep, 
prolonged night-time awakenings, and excessive daytime sleepiness since the age of 1 
year.  
The patient‘s karyotype (high resolution G-banding) was 46, XX.  Genetic testing 
for fragile X syndrome (GC-rich PCR and Southern blot analysis) and molecular 
cytogenetic analysis for the detection of SMS deletions (FISH, Cytocell probe) gave 
negative results.  Screening for variations in the RAI1 coding region identified a 
significant nucleotide change in exon 3 that included a deletion of 4 bp starting at 
nucleotide 2966 (Fig. 7).  This heterozygous novel deletion resulted in a frameshift  
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Fig. 4.  The changing face of SMS339.  Smith-Magenis syndrome (SMS) phenotype 
observed in SMS339 since childhood. A. 7 months old. B. 3 years old. A.-B. Note broad 
forehead, upslanted palpebral fissures, open mouth posture, tented upper lip, and full-
tipped and up-turned nose. C-D.  Note broad nasal bridge.  E. Note mild brachydactyly.  
F. 10 y, note broad nasal bridge and full lips. 
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Fig. 5.  Photos of SMS339 at age 14 years.  A.-B.  Whole body pictures of the patient.  
(A) frontal view, note truncal obesity, lateral inclination of the trunk due to scoliosis, and 
genu valgum; (B) side view, note again the truncal obesity and the lumbar hyperlordosis.  
C.-D. Facial appearance at age 14 y. (C) side view, note the mild retrognathia and the 
cervical kyphosis. (D) frontal view, note broad and coarse face, bushy eyebrows with 
mild synophrys, and full-tipped nose.
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Fig. 6.  Clinical features observed in SMS339.  A.-B. Hands of the patient at age 14 y, 
note the broad palm and the mild brachydactyly.  C. Feet of the patient at age 14 y, note 
the marked brachydactyly, proximal cutaneous syndactyly of toes 2-3, toenail hypoplasia, 
and mild hallux valgus.  D. Plantar view on podoscope showing pes planus and 
brachydactyly.  E.  X-ray images showing dorsal scoliosis of the spine. 
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Fig. 7.  RAI1 mutation analysis in SMS339.  Top: An electropherogram of both 
mutated and normal alleles from the patient, SMS339, is shown.  The patient carries a 4 
bp deletion (AAGA) starting at nucleotide position 2966 on one RAI1 allele.  This 
mutation causes a frameshift and truncation of the RAI1 protein.  Bottom: normal RAI1 
sequence. 
 
SMS339 
Normal 
c.2966delAAGA 
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Table 6.  RAI1 variations in SMS339. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*DNA changes with nucleotide number starting from the ATG in the coding region. 
 
mutation leading to misincorporation of 38 amino acids and truncation of the RAI1 
protein.  Parental DNA analyses were normal.  This de novo mutation was consistent with 
the diagnosis of SMS.   
The patient also carried several RAI1 polymorphisms, including one novel SNP 
(Table 6).  Out of the four polymorphisms identified in this patient, three were in the 
homozygous state and have been reported in the SNP database (Table 5).  In addition, 13 
polyglutamine repeats were present on each allele.   
SMS343 
  SMS343 is a female patient of Caucasian descent referred for mutation screening 
of the RAI1 gene.  FISH analysis of the 17p11.2 region was negative by report.  RAI1 
mutation screening identified one known polymorphism in the homozygous state located 
in the exon 5 region (Table 5).  In addition to this SNP, 14 polyglutamine repeats were 
present on each allele.  This patient was homozygous throughout the exons, which 
Nucleotide change* Amino acid change SNP ID 
2966delAAGA Frameshift/protein truncation Novel mutation 
Polymorphisms 
  
c.269G>C p.Gly90Ala (homozygous) SNP 3803763 
c.493C>A p.Pro165Thr (homozygous) SNP11649804 
c.837G>A p.Gln279Gln (homozygous) SNP 11078398 
c.2773G>A  p.Val925Ile (heterozygous) Novel SNP 
PolyQ tract (PolyQ)13  
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suggests the possibility of an internal deletion of the gene which is non identifiable by 
sequencing.  Hence, additional studies such as aCGH should be performed on this patient 
sample to detect the real cause underlying these features. 
SMS344 
 SMS344 is a 9 year old Caucasian female who was evaluated by geneticists 
between the ages of 4-8.  She was born at 42-weeks gestation and weighed 7 pounds 4 
ounces.  At the age of 8, she weighed 92.2 kg (> 97
th
 percentile), her height was 154 cm 
(> 97
th 
percentile) and head circumference was 58 cm.  She had experienced precocious 
puberty at the age of 7 and had suffered from severe obesity.  She exhibited SMS features 
such as short, square shaped forehead, deep set eyes with horizontal palpebral fissures, 
prominent nasal bridge, small upturned nose, strabismus, hearing loss, speech and 
developmental delays.  Some of other features included high-arched palate, sloping 
shoulders and mild waddling gait.  
 Laboratory data included a normal karyotype, negative FISH for 15q and17p11.2 
deletion, Fragile X and Prader-Willi/Angelman syndrome and normal chromosomal 
microarray.  RAI1 mutation screening identified three known polymorphisms, with two of 
them in the heterozygous state (Table 5).  No other deleterious nucleotide changes were 
identified in this patient. 
SMS345 
 SMS345 is a Caucasian male patient exhibiting clinical signs of SMS.  FISH 
analysis of 17p11.2 region as well mutation screening of RAI1 gene did not identify any 
deletion.  This patient carried two non-disease causing polymorphisms, both in the 
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homozygous state (Table 5).  In addition, 14 polyglutamine repeats were present on each 
allele.  This patient was homozygous throughout the exons, which suggests the possibility 
of an internal deletion of the gene which is non identifiable by sequencing.  Hence, 
additional studies such as aCGH should be performed on this patient sample to detect the 
real cause underlying these features. 
SMS346 
 SMS346 is 12 year old male of Caucasian descent, who was evaluated at age of 
11 due to his history of developmental delay and dysmorphic features.  In addition to 
these features, the patient also had some other features consistent with SMS such as 
aggressiveness, self-injurious behaviors including head-banging and hand-flapping, sleep 
problems, midface hypoplasia, tented upper lip, brachydactyly, and seizures.  At the time 
of evaluation, his height was 127 cm (< 5
th 
percentile), his weight was 48 kg (> 97
th
 
percentile) and head circumference was 54.5 cm.  
Laboratory studies included negative results for Down syndrome and 17p11.2 
deletion by FISH and normal aCGH.  Sequencing of the RAI1 gene identified four 
polymorphisms and 14 polyglutamine repeats on each allele.  Three of the 
polymorphisms were located in the exonic region and two of these three were present in 
homozygous state (Table 5).  The fourth polymorphism (c.5710-22G>T) present in 
heterozygous state was identified in the intronic region and is of unknown significance.  
Although this novel nucleotide change may cause alternate splicing of the RAI1 gene 
which would disrupt a functional protein domain, additional studies are required to 
confirm this hypothesis. 
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SMS348 
 SMS348 is 12 year old half Caucasian, quarter African-American and quarter 
Japanese male, who was born at 32 weeks gestation with a weight of 6 pounds 12 ounces. 
Since early childhood, he had suffered from behavioral disturbances, sleep problems, 
obesity, ear infections and speech delay.  He was diagnosed with bipolar disorder and had 
been on medications which might have contributed to his obesity.  The physical 
examination at the age of 11 showed his weight as 79kg (> 95
th
 percentile), his height as 
152 cm (50
th – 90th percentile) and head circumference as 55 cm.  He also exhibited other 
features such as broad, square face, midface hypoplasia, broad nasal bridge, tented upper 
lip, flat face, synophyrs and brachydactyly that were also consistent with SMS.  Family 
history was significant as the patient‘s father and two of his paternal half-siblings had 
bipolar disorder and mother had been diagnosed with Charcot-Marie-Tooth disease type 
1A (CMT1a).  
Laboratory data included normal karyotype and negative result for Fragile X 
syndrome.  Although aCGH and RAI1 mutation screening ruled out SMS, the patient was 
identified with duplication of chromosome 17p12 region that included PMP22.  This 
finding is diagnostic for CMT1a and is consistent with the CMT1a diagnosis in patient‘s 
mother.  RAI1 mutation screening identified five known polymorphisms, and all of them 
were present in the heterozygous state (Table 5).  
SMS349 
 SMS349 is 19 year old male of Latvian descent with features consistent with 
SMS. His craniofacial features included midface hypoplasia, brachycephaly, frontal 
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bossing, broad nasal bridge, down turned upper-lip, up-slanting eyes and prognathism.  
His ocular/otolaryngological abnormalities included strabismus, myopia, and hoarse 
voice.  He exhibited some other manifestations such as dental abnormalities, kidney 
abnormalities, obesity, pes planus, scoliosis, developmental delay, sleep disturbance and 
self-injurious behavior (nail yanking).   
Laboratory data included normal aCGH and sequencing of the RAI1 gene which 
identified four polymorphisms and three of them were in heterozygous state (Table 5).  
One of the four polymorphisms was novel and not listed in the NCBI SNP database.  No 
other studies have been performed on this patient sample. 
SMS351 
 SMS351 is 4 year old Caucasian male with broad nasal bridge, down-turned 
upper lip, brachydactyly, frequent ear infections, sleep disturbance, developmental delays 
and self injurious behaviors such as polyembolokoilomania, self-biting, and head banging 
in addition to other features consistent with SMS.  He was evaluated at the age of 3, and 
his clinical examination shows that his weight was 17 kg, height was 95.4 cm and head 
circumference was 51.2 cm. 
 Laboratory findings included negative 17p11.2 deletion by FISH and normal 
aCGH results.  Mutation analysis on the RAI1 gene identified three polymorphisms 
(Table 5).  Two of the polymorphisms were known and located in the exonic region, and 
one of these two SNPs was in homozygous state.  Although the third polymorphism was 
novel and located in the intron 5 region, this variant was present in both his parents. 
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SMS356 
 SMS356 is 11 year old female of Austrian descent with features consistent with 
SMS including neurological features (sleep disturbance, mental retardation, hypotonia, 
speech and motor delay), craniofacial features (brachycepahly, midface hypoplasia, 
broad-square face, and short stature) behavioral features (self-hugging) and self-injurious 
features (polyembolokoilomania).  
Laboratory results included negative FISH for 17p11.2 deletion.  On performing 
RAI1 mutation screening, we identified five heterozygous polymorphisms, all reported in 
the SNP database (Table 5).  Besides these changes, no other abnormalities were 
identified in SMS356. 
 
Comparison between mutation and non-mutation cases 
 We compared thirty-two clinical features commonly associated with the RAI1 
mutation cases to the cohort of non-mutation cases (Table 7).  All features were scored as 
present (+), absent (-) or data not available (N) (data not shown).  These scores were then 
recalculated to obtain the percentages and compared with each other.  The results (Table 
7) indicated that all features were consistent between the two groups.  These features 
included craniofacial/skeletal characteristics such as synophyrs, midface hypoplasia, 
tented upper lip, scoliosis and short stature.  Neurological/behavioral similarities included 
mental retardation, developmental delay, hypotonia, sleep disturbance, self-hugging and 
seizures.  Other features that showed consistency included self injurious behavior such as 
head-banging/skin picking/finger chewing; ocular abnormalities such as strabismus and 
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myopia; otolaryngological abnormalities such as chronic ear infections and hearing loss; 
and lastly, pes planus (flat feet) and dental anomalies.  Not many RAI1 mutation patients 
have been reported with cardiovascular anomalies; SMS339 from present study was one 
of the exceptions.  There were no significant differences that existed between the 
mutation and non-mutation cases and hence, their referral for RAI1 sequencing was right. 
 
Refine the sequencing methodology 
 RAI1 is a large gene consisting of 6 exons, of which 3-6 are coding exons (Fig. 
2a).  These coding exons encode a 1906 amino acid protein with the molecular weight of 
203 kDa.  Out of four coding exons, exon 3 is the largest exon composed of 5580 bp 
nucleotides and encodes > 98% of the protein.  Exons 4, 5 and 6 are comparatively 
smaller exons composed of 93 bp, 49 bp and 12 bp respectively.  Sequencing of the RAI1 
gene with twelve sets of overlapping primers was a tedious, time-consuming and 
expensive process.  To make the sequencing methodology time- and cost-effective, the 
protocol was refined (Appendix A).  Two rounds of sequencing with different sets of 
primers were planned (Fig. 8).  The first round of sequencing included PCR amplification 
with primers (e.g. forward primer of 1
st
 set and reverse primer of the 2
nd
 set) covering big 
fragments (~ 2 kb) of the coding region and the amplimers sequenced with forward 
primer of 1
st
 set and reverse primer of the 2
nd
 set.  This process saved time and cost of 
performing two PCR amplifications and sequencing with two sets of forward and reverse 
primers.  If and only if the first round of sequencing did not cover the entire region, then 
it was followed by second round of sequencing which included individual sets of primers  
  
% RAI1-
mutations 
(n=14) 
Fisher's 
exact test  
(p-value) 
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   SMS 
Features 
% Non-
mutations
$
 
(n=11) 
% RAI1- 
mutations
# 
(n=14) 
Fisher's exact 
test  
(p-value) 
Gender (Male) 54 (n=11) 57 (n=14) 1 
Craniofacial/Skeletal 
   Brachycephaly 67 (n=9) 91 (n=11) 0.28 
Midface hypoplasia 78 (n=9) 82 (n=11) 1 
Broad, square face 78 (n=9) 92 (n=12) 0.55 
Tented upper lip 67 (n=9) 75 (n=12) 1 
Prognathism (relative to age) 34 (n=3) 87 (n=8) 0.15 
Synophrys 45 (n=9) 33 (n=12) 0.67 
Brachydactyly 60 (n=5) 73 (n=11) 1 
Short stature (<5
th
 centile) 33 (n=9) 25 (n=12) 1 
Scoliosis 50 (n=8) 33 (n=12) 0.65 
Neurological/Behavioral 
   Mental retardation 100 (n=9) 86 (n=14) 1 
Speech delay 100 (n=9) 100 (n=14) 1 
Motor delay 100 (n=9) 100 (n=14) 1 
Hypotonia 57 (n=7) 67 (n=12) 1 
Sleep disturbance 100 (n=9) 100 (n=14) 1 
Self-hugging 50 (n=8) 77 (n=13) 0.34 
Seizures 43 (n=7) 33 (n=12) 1 
Overeating 100 (n=4) 87 (n=8) 1 
Self-injurious behavior 
   Head-banging  45 (n=9) 77 (n=13) 0.19 
Skin picking/finger-chewing 50 (n=6) 80 (n=10) 0.30 
Onychotillomania 37 (n=8) 69 (n=13) 0.20 
Polyembolokoilomania 62 (n=8) 77 (n=13) 0.63 
Ocular abnormalities 
   Strabismus 57 (n=7) 45 (n=11) 1 
Myopia 75 (n=4) 64 (n=11) 1 
Otolaryngologic 
   Chronic ear infections 50 (n=8) 75 (n=12) 0.36 
Hoarse, deep voice 50 (n=4) 83 (n=12) 0.24 
Hearing loss 37 (n=8) 27 (n=11) 1 
Other manifestations 
   Cardiovascular anomalies 0 (n=7) 17 (n=12) 0.5 
Pes planus 75 (n=4) 62 (n=8) 1 
Renal anomalies 12 (n=8) 10 (n=10) 1 
Dental anomalies 62 (n=8) 67 (n=9) 1 
Overweight/Obese 86 (n=7) 87 (n=8) 1 
Table 7.  Phenotypic comparison between mutation and ‘SMS-like’$ cases. 
(N) Information not available. 
# 
Includes previous Elsea lab cases + new mutation case. 
$
 Includes non-mutation cases from present study. 
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covering an approximately 1 kb region of the coding exons and then sequencing with the 
forward or reverse primers that covered the remaining region of the exons.  In addition to 
this, new internal primers were also designed to check for novel SNPs or for sequencing 
for the remaining uncovered region.  Along with the new primers, novel SNPs and 
mutations have been added to the RAI1 genomic sequence used for the sequence 
alignment and analysis (Appendix B).  This new protocol of sequencing RAI1 gene has 
greatly improved the screening technique for mutation analysis by making the process 
faster and cost effective. 
    
 
 
       
  
  
 
Fig. 8 Schematic explaining the two rounds of sequencing.  The first round includes PCR 
amplification with SHE 323/324 set covering larger fragments.  The second round includes 
PCR amplification with individual sets of primers (SHE323/324 and SHE325/326). 
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Discussion 
Identification of mutations and polymorphisms 
We reported twelve patients exhibiting SMS features but had a normal FISH 
result for 17p11.2 deletion.  On analyzing their DNA sample by sequencing of the RAI1 
gene, only one of them was identified with a novel RAI1 mutation.  The novel mutation 
identified in our patient was de novo as it was absent in the parental DNA, although the 
possibility of germline mosaicism cannot be ruled out.  This mutation caused a significant 
nucleotide change in exon 3 that included a deletion of 4 bp starting at nucleotide 2966 
(Fig. 7).   This heterozygous novel deletion should result in a frameshift mutation leading 
to misincorporation of 38 amino acids and truncation of the RAI1 protein.  This novel de 
novo mutation was consistent with the diagnosis of SMS.  Previous studies in our lab and 
others have identified several patients with RAI1 mutations, which along with this patient, 
bring the total number of individuals with sporadic RAI1 mutations to 19 ( Fig. 9) (4, 8, 
10, 15, 20, 40).   
Our 17 year old patient was the first SMS case with a demonstrated RAI1 gene 
mutation and absence of frank mental retardation.  She showed a physical phenotype 
characterized by being mildly overweight, and craniofacial and skeletal anomalies 
evocative of SMS (broad face, bushy eyebrows, synophrys, upslanting palpebral fissures, 
full-tipped nose, mild retrognathia, dorsolumbar scoliosis, brachydactyly of fingers and 
toes, and pes planus).  Other physical features were hoarse voice, dry skin, tricuspid 
regurgitation, and a history of constipation and, until early infancy, hypotonia.  The 
clinical picture was, however, dominated by the behavioral abnormalities, which, like in 
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most SMS patients, began in early childhood and increased in severity with progressing 
age.  The patient displayed weak relational and social skills, obsessive thinking, tendency 
to depressed mood, stereotypies, significant maladaptive behaviors (temper tantrums, 
disobedience, impulsivity, verbal aggressiveness, attention seeking, and prolonged 
crying), self-injurious behaviors (skin-picking of the legs, onychotillomania, self-
hugging, polyembolokoila-mania associated with recurrent urinary tract infections, 
cutting locks of her own hair, tearing away her eyebrows, and writing and painting the 
skin, mouthing of hands and objects, and grinding of the teeth), and sleep disturbances 
(difficulty falling asleep, prolonged night-time awakenings, and excessive daytime 
sleepiness).   
The behavioral phenotype and the sleep disturbances of SMS patients can be 
considered as real diagnostic ―handles‖ in the diagnosis of this syndrome.  Also in our 
case, these cardinal signs, along with some physical features (mainly the brachydactyly of  
toes and the mild but suggestive facial dysmorphisms), were the pivotal clinical 
manifestations that pointed out the possibility of the patient having SMS.   
It is important to note that, although the patient showed some learning disabilities 
and certain weaknesses in sequential processing and short-term memory, her IQ fell in 
the low normal range, and she did not have mental retardation.  In the medical literature,  
no cases of SMS with IQ greater than 75 have been reported, and our patient was the first 
SMS case with an absence of frank mental retardation (10).   
When compared with SMS patients that have deletions, the few reported subjects 
with RAI1 mutations are more likely to exhibit overeating, overweight/obese habits, dry 
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Fig. 9.  RAI1 variations identified in SMS patients.  The schematic illustrates 
mutations and polymorphisms identified in RAI1 gene. The coding exons are black and 
non-coding exons are orange. All the mutations are located in exon 3 which encodes 
>98% of the protein. The underlined variations were identified in the twelve patients 
evaluated in present study. 
Source: Slager et al. 2003; Bi et al. 2004; Bi et al. 2006; Girirajan et al. 2005; 
Girirajan et al. 2006; GeneDx; Present study 2009 
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skin, muscle cramping, less severe motor delay, higher functioning, and self-injurious 
behaviors such as polyembolokoilamania, skin-picking and self-hugging.  Moreover, they 
tend to not have organ system involvement.  In particular, very few RAI1 mutation 
patients have been reported to have cardiac or renal anomalies.  Excluding muscle 
cramping, our patient showed all the clinical features typically associated with SMS due 
to mutations in RAI1.  However, it is interesting to note that she was the first case with an 
RAI1 mutation having a cardiac anomaly of mild tricuspid regurgitation.  This finding 
partially enlarges the spectrum of symptomatic effects of RAI1 mutations, which is 
clearly not yet completely known because of the limited number of recognized patients 
and an understandable selection bias toward the more severe and typical cases of SMS.   
We also identified several polymorphisms in these patients.  Most of them were 
known SNPs from the database, along with four novel SNPs, two of which were located 
in the intronic regions (Table 4).  Along with these novel SNPs, the total number of SNPs 
identified in the coding sequence of the RAI1 gene is 13 (Fig. 9).  Except for a few that 
were in homozygous state, the majority of these SNPs were heterozygous.  The intronic 
SNPs that were found in SMS346 and SMS351 are located in intron 5.  At present, we 
are unaware of the potential cause and effect of these exonic and intronic SNPs and 
hence, further studies need to be performed to evaluate their role in causing SMS 
features.  
Future studies to improve diagnosis of SMS 
The incidence rate of this neurodevelopmental disorder is estimated to be 
1:15,000-25,000 births, but it seems likely that these figures represent an underestimate 
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(10).  Many of these patients were initially diagnosed with some other syndrome, but 
eventually when tested for 17p11.2 by FISH or RAI1 sequencing, they were identified 
with deletion or mutation, and were correctly diagnosed with SMS. 
For example, our patient (SMS339) was initially diagnosed with mood disorder 
associated with behavioral anomalies, and the psychiatric signs were not recognized as 
part of a known syndrome.  It is probable that other ―psychiatric patients‖ actually have 
SMS, and it is believed that this condition could easily go undiagnosed when the 
cognitive impairment is lacking or the severity of mental retardation falls in the mild or 
borderline range.  On the other hand, both the variable expression of the clinical picture 
and the still limited knowledge of the syndrome by clinicians are the principal reasons for 
considering the current incidence rate figures of SMS as an underestimate.  Obtaining the 
correct diagnosis is of critical importance for the family and the patient, particularly so 
that the patient can obtain the necessary educational, therapeutic, and medical services 
needed for an individual with SMS. 
 Future studies are important also for those patients that are negative for deletion 
of 17p11.2 region or mutation of RAI1 gene, but clearly exhibit features consistent with 
SMS. Some of these cases have been evaluated for the alternative diagnosis of SMS, as 
suggested by Elsea and Girirajan (2008) such as Prader-Willi, Angelman, Down, and 
Fragile X syndromes (Table 8), but the laboratory findings were negative.  In my study, 
11/12 patients belong in this category and are classified as ―SMS-like‖ cases.  There 
might be several possibilities that could lead to the appearance of ‗SMS-like‘ phenotype. 
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Table 8:  Alternative diagnosis of Smith-Magenis syndrome.         
 
Syndrome OMIM No. Clinical Featuresa 
9q34 deletion 
syndrome 
#61253, *607001  Mental retardation, brachycephaly, flat face, midface hypoplasia, 
tented upper lip, short nose, hypertelorism, synophyrys, 
prognathism, hypotonia, cardiac anomalies, seizures, hearing 
loss, sleep disturbance, obsessive-compulsive disorders, and 
stereotypic movement 
Down syndrome 
(Trisomy 21) 
#190685, *602917, 
*605296, *605298, 
*604829  
Mental retardation, hypotonia, short stature, brachycephaly, 
epicanthic folds, upward slanting palpebral fissures, flat facies, 
congenital heart defects, Brushfield spots (iris), single palmar 
crease, brachydactyly, small and low-set ears, obtrusive sleep 
apnea, and cardiac and endocrine problems 
Williams 
syndrome 
(del(7)q11.23) 
#194050, *130160, 
*601329, *603432, 
*604318, *601679 
Mental retardation, characteristic ‗elfin‘ facies, supravalvular 
aortic stenosis, hypercalcemia, prenatal growth retardation, short 
stature, lack of depth perception, and friendly, loquacious 
personality 
Prader-Willi 
syndrome 
(paternal 
del(15)q11-q13) 
#176270, *182279, 
*602117 
Mental retardation, speech and motor delay, brachycephaly, 
almond-shaped eyes, down-turned mouth with thin upper lip, 
hypotonia, short stature, gait abnormalities, hyperphagia, genital 
hypoplasia, and self-injurious and obsessive-compulsive 
behaviours  
22q11.2 deletion 
syndrome 
(DiGeorge/ 
velocardiofacial 
syndromes)  
#188400, #192430, 
*602054 
Congenital heart disease, velopharyngeal insufficiency, cognitive 
and motor delay, feeding difficulties, immune deficiency, 
hypocalcemia, hearing loss, and skeletal abnormalities  
Sotos syndrome #117550, *606681 Mental retardation, hypotonia, cognitive and motor delay, 
feeding difficulties, tall stature, macrocephaly, malar flushing, 
frontotemporal hair sparsity, down slanting palpebral fissures, 
seizures, scoliosis, and cardiac and renal abnormalities 
aSummarized from Online Mendelian Inheritance in Man (OMIM)                                                                                                         
  Source – Elsea and Girirajan, 2008 
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It is possible that RAI1 interacts with other genes or proteins via multiple 
pathways that could lead to an SMS or an SMS-like phenotype.  The amino acid 
sequence motifs such as bipartite nuclear localization signal and PHD domain of the 
RAI1 gene are found to be related to the transcription factor stromelysin-1 platelet 
derived growth-factor-responsive element binding protein (TCF20) which strongly 
suggests that RAI1 could be a transcription factor modulating the expression of genes 
involved in a variety of cellular functions.  The ‗SMS-like‘ phenotype showed by our 
patients confirmed from a clinical point of view that further studies are required to fully 
understand the role played by RAI1 in the biochemical and molecular pathways 
important for development, cognition, and behavior and thus, improve the diagnosis of 
SMS. 
 
Conclusions 
 Smith-Magenis is a complex and contiguous gene syndrome affected by several 
genes in 17p11.2 region.  RAI1 gene is one of the 25 genes located in the SMS critical 
region and mutation screening by RAI1 sequencing has proven that mutation in this gene 
causes SMS.  RAI1 mutations are mostly de novo as they are not present in the patient‘s 
parents. Including the cohort of patients with 17p11.2 deletion and RAI1 mutations, there 
exist a group of patients with familial mutations in the RAI1 gene.  These familial 
mutations have complicated the diagnosis of SMS, due to their clinically normal parents 
and siblings.  Besides the patients diagnosed with SMS, there is one more category of 
patients with ‗SMS like‘ phenotype.  Although these patients have SMS phenotypes, they 
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are negative for 17p11.2 deletion or RAI1 mutation, which suggests a role played by a 
different gene/modifier which might be upregulating or downregulating the RAI1 gene 
and contributing to the phenotype.  This dosage-sensitive effect of RAI1 can be evaluated 
in zebrafish models by characterizing rai1 gene expression in the presence and absence 
of its inducer. 
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CHAPTER 3: Cloning and sequencing of zebrafish rai1 gene 
 
 
Introduction - Zebrafish model 
 Zebrafish (Danio rerio), a tropical freshwater fish, serves as a very important 
model organism in the field of scientific research.  It was first used as a model organism 
in the 1980‘s by George Streisinger, who induced mutations in mature germ cells of 
embryos by gamma-rays and opened the arena of studying mutagenesis and gene 
regulation by performing forward genetic screens in zebrafish (44).  This model presents 
many advantages over other model organisms such as rapid generation time, high 
fecundity, external development, transparency of embryos, low cost and simpler staining 
techniques for manipulation of development at all stages.  Comparative genomics shows 
the similarity between genomes of human and zebrafish.  Humans and zebrafish have 
diverged ~ 420 million years ago but have similar skeletal cell structure, including neural 
crest cells (28). This makes zebrafish a useful resource in studying cranio-facial and 
neurological development observed in SMS patients.  
 
 
 
 
   
46 
 
Broad period of embryogenesis 
 The seven stages of zebrafish embryogenesis are as follows: zygote (0- 0.75 
hours), cleavage (0.75 – 2.25 hours), blastula (2.25 – 5.25 hours), gastrula (5.25 – 10.33 
hours), segmentation (10.33 – 24 hours), pharyngula (24 – 48 hours) and hatching (48 – 
72 hours) (27).  The zygote stage is 1-cell stage where the chorion swells and detaches 
from the newly fertilized embryo.  The cytoplasm streams away from the vegetal pole 
and towards the animal pole to form a blastodisc.  This defines the first stage of 
embryogenesis. In the second stage known as the cleavage stage, six cleavages (2 cells to 
64 cells) occur every fifteen minutes in regular orientations giving rise to 3 tiers of 
blastomeres.  Blastula stage is defined as the stage where the 3 tiers further divide to 11 
tiers of blastomeres and the marginal blastomeres form rows of yolk synctial layer (YSL).  
The YSL continues to develop and the blastula flattens and forms a sphere between the 
yolk and blastodisc.  This sphere begins to bulge towards the animal pole to form a 
blastoderm.  By the end of the blastula stage, the blastoderm covers 30% of the yolk sac.  
In the gastrula stage, the blastoderm continues to cover a larger fraction of the yolk (~ 
90%) forming a germ-ring and then an embryonic shield.  By the end of this stage, the 
embryo develops 90% epiboly, brain and notochord rudiments.  The fifth stage of 
development is marked by segmentation of somites (1 – 26+) which leads to the 
development of primordial regions such as hindbrain-midbrain boundary, trunk, tail, and 
lens.  The pharyngula stage is an important stage for comparison of the morphologies of 
the diverse vertebrates according to Baer‘s famous law (25).  At this stage, the embryo 
develops heartbeat, pigmentation, primary body organs such as brain and retina.  By 48 
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hpf (hours post fertilization), the differentiation of neurons and neural crest cells takes 
place which further differentiates into cartilage.  The yolk size starts to reduce and the 
size of the head starts increasing.  The final stage of zebrafish embryogenesis, the 
hatching stage is when pectoral fin buds and blades are formed, morphogenesis of the 
organs is completed, and the embryo hatches.  At the end of the third day or hatching 
period and afterwards, they are known as ‗larvae‘ and after 90 days post-fertilization, 
they are known as ‗adults‘.  
rai1 gene in zebrafish   
 A single putative ortholog of the rai1 (XM 001333125, LOC793412) gene was 
predicted in zebrafish but not fully annotated (Fig. 10).  This gene is a homologous to the 
RAI1 gene and conserved in human, chimpanzee, dog, mouse, rat and chicken (9). The 
putative gene maps to chromosome 3 and is made up of 3 exons composed of 5824 bp 
nucleotides and encodes a 1936 amino acid protein.  Zebrafish putative gene sequences 
based on computation analysis are added to the NCBI HomoloGene database and 
Genome browser.  Comparing the putative zebrafish rai1 gene sequence with available 
transcripts, an expressed sequence tag (EST) (clone 2691424) was identified to have the 
5‘ end of the gene along with some UTR region, approximately 500 bp (Fig. 11).  As this 
suggested the EST contained the full-length rai1 gene, it was bought from Open 
Biosystems and sequenced with overlapping forward (F) primers (Table 9).  Sequencing 
the full-length clone was important because this clone was generated from a different 
strain than the sequence data in the Genome Browser, and accurate sequence is required 
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Fig. 10.  Putative structure of zebrafish rai1 gene.  LOC793412 maps to chromosome 
3 of the zebrafish genome and is composed of 3 exons. This putative structure is based on 
the computational analysis and projection studies performed by NCBI Homologene 
database. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11.  Schematic of rai1 Expressed Sequence Tag (EST).  EST was identified to 
have a 5‘end and some UTR region. This suggested that it contained the full-length rai1 
and was used for sequencing the 5‘end of the rai1 gene. 
I II II
I 
ATG 
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to design an antisense knockdown (morpholino) and perform rescue experiments. Once 
the accurate sequence of zebrafish rai1 gene is annotated, this model organism will serve 
as a unique and powerful system to study dosage sensitivity of rai1 and identify new and 
existing gene networks and functions. 
 
Materials and methods 
 
Isolation of DNA from plasmid 
DNA was isolated from the plasmid containing the full-length clone 
(EXELIXIS2691424) of zebrafish rai1 using DNA midi kit (Qiagen, Valencia, 
California, USA).  The DNA samples were treated with RNase to eliminate 
contamination by RNA.  The isolated DNA was quantified by a spectrophotometer at the 
absorbance ratio of 260/280. 
PCR and sequencing 
 PCR amplification of the plasmid DNA was performed initially by using two 
different combinations of the vector primers (M13F (gtaaaacgacggccagt) and M13R 
(caggaaacagctatgac); T7F (taatacgactcactatagg) and M13R (caggaaacagctatgac)).  Several 
overlapping primers were also designed for sequencing the M13F/M13R PCR product to 
obtain the remaining gene sequence that was not covered by the initial set of primers 
(Table 9).  PCR reaction mix and conditions were followed as described in Chapter 2 
(polymerase chain reaction). Sequencing was performed at the Virginia Commonwealth 
University Sequencing Core using the protocol described in Chapter 2 (Sequencing).  
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Sequence analysis 
The chromatograms results were received from the sequencing core and the 
sequencing results from the forward primer were analyzed by comparing the results with 
the predicted rai1 sequence visually by looking for variations (nucleotide change) and 
sequence quality.  The predicted rai1 sequence was obtained from Genome Browser and 
NCBI. A poly A tail was encountered at 3720 bp (after SalI site) and sequencing results 
became unclear (Fig. 12). 
Table 9.  Overlapping primers for sequencing rai1 gene 
Forward primer Sequence 
covered 
M13: 
gtaaaacgacggccagt 
490 bp 
SHE608: 
gtacatgagcgaaggtcac 
460 bp 
SHE610: 
gtaaggtcgccggaacaatac 
952 bp 
SHE614: 
catggaccgagaggatg 
828 bp 
SHE633:  
atcatcacatcgattgt 
656  bp 
SHE635: 
agtccaaagccttgtccta 
330 bp 
JL502: 
caactgtggcatcagtagctaaaggc 
1818 bp 
SHE646:  
gcgcccagatctaagtgacg 
897 bp 
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Collect cultivated embryos 
Overnight tanks that separated three male from three female fish were set-up in 
the afternoon.  Mating took place in the morning and embryos were collected in a 10 cm 
petri dish after 1-2 hours.  Each petri dish contained ~ 80 embryos and the dish water was 
maintained by removing empty chorions and deformed embryos. 
TRIzol treatment 
 Collected embryos were incubated at 28.5°C until they reached the required stage. 
At 72 hpf, a total of 30 embryos were homogenized in 1 ml of TRIzol reagent and stored 
at -20°C until ready to isolate RNA.  
RNA extraction 
 Total RNA was extracted from TRIzol treated (72 hpf) embryos using the RNA 
preparation kit (Invitrogen), according to the manufacturer‘s instructions. 
Reverse-transcriptase PCR (RT-PCR) 
 First strand cDNA synthesis was performed on the extracted RNA from 72 hpf 
embryos according to the manufacturer‘s protocol (Stratagene Accuscript protocol) using 
1 µl of 1-2 ug of total RNA, Accuscript RT buffer, Accuscript RT, oligo dT, DTT 
(0.1M), Rnasin and dNTP mix (10 mM).  
PCR and sequencing 
 cDNA obtained from RT was PCR amplified with overlapping primers (Fig. 12) 
designed between the SalI site and the 3‘ end of the putative rai1 gene sequence (JL502F 
(caactgtggcatcagtagctaaaggc) and SHE647R (cgtggtatgcagtcctcagg); SHE646F 
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(gcgcccagatctaagtgacg) and SHE650R (tcacacacttaccttgtgtttcgg)).  PCR reaction mix and 
conditions were followed as described in Chapter 2 (polymerase chain reaction).  
Sequencing was performed at the Virginia Commonwealth University Sequencing Core 
using the protocol described in Chapter 2 (Sequencing).  
Sequence analysis 
The chromatograms results were received from the sequencing core, and the 
sequencing results were analyzed as described in Chapter 3 (sequence analysis).  
Cloning rai1 PCR products 
 PCR products of the correct size were purified by gel extraction using the Qiagen 
Gel Extraction kit (Qiagen Inc, Valencia, California, USA).  Purified PCR products (~ 10 
ul) were treated with 0.25 ul of Taq polymerase (5u/ul) and 0.25 ul of dNTP (10 mM) at 
72° for 10 mins.  These products were then TOPO
® 
cloned into pCR
®
2.1-TOPO
® 
[646/650] /pCR
®
4-TOPO
®
 [502/647] vector using the TOPO
®
 cloning kit by Invitrogen 
(CA) (Fig. 13).  The protocol was revised as follows: the ligation reaction was incubated 
for 30 mins at 22°C, the TOPO- rai1 construct was transformed into One-Shot
®
 - Top F‘ 
chemically competent E-coli cells and incubated on ice for 30 mins, and 50 ul of 
transformation mix were spread on LB plate with 50 µg/ml of kanamycin and incubated 
at 37°C for overnight.  Colonies were grown in a culture with 5 ml of LB media and 2.5 
ul of kanamycin (100 µg/ml).  The culture was used to isolate DNA using the DNA mini-
prep kit by Fermentas (Burlington, Canada).  PCR amplification of the isolated DNA was 
performed by using the rai1 specific primers (JL502/SHE647; SHE646/650) to confirm 
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Fig. 12.  Schematic illustrating the end of EST and overlapping primers used for 
obtaining 3’ end.  Poly A tail was encountered at 3720 bp (cDNA ends). Overlapping 
primers JL502/SHE647 and SHE646/ SHE650 were used for PCR amplification for 
obtaining 3‘end of rai1 gene.  
 
 
 
 
 
 
 
Fig. 13.  Schematic representation of the three rai1 clones. The three fragments of the 
zebrafish rai1 gene were present in three different vectors. (A) EST containing the 5‘end 
cloned into pCCM114 vector. (B) JL502/647 fragment cloned into pCR 4 –TOPO vector 
and (C) SHE646/650 fragment cloned into pCR 2.1- TOPO vector.
pCCM114 (A) 
pCR 4-TOPO (B) 
pCR 2.1-TOPO (C) 
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 the presence of the insert.  DNA was also digested with restriction enzymes to check for 
the insert (EcoRI) and its orientation in the vector (SacI – SHE646/650 fragment, SpeI 
and BglII – JL502/SHE647 fragment).  Glycerol stocks were made of the rai1 fragments 
for storage purposes. 
 
Ligation of rai1 cDNA fragments  
 The three rai1 fragments in three different vectors were ligated together to create 
a full length rai1 clone.  The SHE646/650 and JL502/647 fragments present in two 
different vectors were double digested with BglII and SpeI enzymes.  The digested 
products were gel purified using the Qiagen Gel Extraction kit (Qiagen Inc, Valencia, 
California, USA).  Purified product (JL502/647) was treated with calf intestinal 
phosphatase (CIP) to prevent recircularization of the cloning vector.  It was further 
treated with the Qiagen gel purification kit (Qiagen Inc, Valencia, California, USA).  
This was followed by the ligation of the JL502/647 fragment (JL502/647 + pCR 4 vector) 
and SHE646/650 (insert in pCR 2.1 vector) using T4 DNA ligase and incubating it 
overnight at 14° C (Fig. 14).  Once the ligation was complete, the pCR 4.TOPO- JL 
502/650 rai1 construct was transformed into One-Shot
®
 Top F‘ chemically competent E-
coli cells and incubated on ice for 10 mins, heat shocked for 40 seconds at 42°C and 
incubated at 37° for 90 mins after the addition of LB.  The transformations (~300 µl) 
were spread on LB plates with 50 ug/ml of kanamycin and incubated at 37°C overnight.  
Positive colonies were grown in a culture with 2 ml of LB media and 2.5 ul of ampicillin 
(100 µg/ml).  The culture was used to isolate DNA using the DNA mini-prep kit by  
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Fig. 14.  Ligation of two rai1 constructs at the 3’end.  JL502/647 fragment (JL502/647 + pCR 4 vector) and SHE646/650 
(insert in pCR 2.1 vector) were double digested with BglII and SpeI and ligated with T4 DNA ligase. 
 
                                               
                                                                      
BglII 
SpeI 
BglII 
SpeI 
SpeI 
BglII 
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Fig. 15.  Ligation of 5’ end with 3’end.  JL502/650 and pCCM114 containing the EST were double digested with NotI and 
SalI enzymes and ligated with T4 DNA ligase.
NotI 
SalI 
SalI 
SalI 
NotI 
NotI 
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Fermentas (Burlington, Canada).  The JL502/650 DNA was digested with NotI and SpeI 
to confirm the size and orientation of the inserts.  This was followed by sequencing of the 
junction between JL502/647 and SHE646/650.  The JL502/650 fragment was then ligated 
with the 5‘end of the gene (1st fragment) in the pCCM114 vector (Fig. 15).  The 
JL502/650 and pCCM114 constructs were double digested with NotI and SalI enzymes.  
The JL502/650 + vector (6.4 kb) was also treated with CIP to prevent recircularization. 
These products were then gel purified using the gel purification Qiagen kit, followed by 
the ligation of the JL502/650 construct (JL502/650 + pCR 4 vector) and 5‘ end  (insert in 
pCR 2.1 vector (~3720 bp)) using T4 DNA ligase and incubation overnight at 14° C (Fig. 
15).  Once the ligation was complete, the pCR 4.TOPO- full length rai1 construct was 
transformed into E-coli cells as mentioned above.  Colonies were grown in a culture with 
2 ml of LB media and 2.5 ul of ampicillin.  The culture was used to isolate DNA using 
the DNA mini-prep kit by Fermentas (Burlington, Canada).  The full length rai1 DNA 
was then digested with SpeI to confirm the size of the insert.  This was followed by 
sequencing of the full length zebrafish rai1 gene using rai1 specific primers on the 5‘ end 
(JL502/ SHE650) to confirm the junctions. 
 
Results 
 
Full-length rai1 gene sequence 
 The sequence obtained from the ligated rai1 plasmid (pCR 4 vector) had 99.5% 
similarity with the putative rai1 sequence published in the NCBI database.  Although 
nucleotide changes were identified in our full-length rai1 clone, this could be the result of 
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the different strain of fish used in our study or the putative sequence obtained from 
computational study was inaccurate.  This full-length rai1 sequence will serve as a 
reagent for morpholino studies to eventually provide a better understanding of the rai1 
gene and its role in causing cranio-facial and neurological defects.  
 
Discussion 
Analysis of rai1 in zebrafish  
 A full length cDNA encoding the rai1 gene from zebrafish was cloned by RT-
PCR of two fragments (3‘ end) and ligation of these fragments with an EST (5‘ end). 
Zebrafish rai1 has an open reading frame coding for 1935 amino acids.  The alignment of 
the zebrafish rai1 with human RAI1 amino acid sequence shows 27 % identity (Fig. 16).  
In regards to the polyglutamine region, human RAI1 is composed of fourteen glutamine 
repeats.  But in all other species including mouse and rat, the polyglutamine region 
generally includes fewer repeats.  As shown in Fig. 16, zebrafish rai1 contains two Qs in 
the vicinity of the human glutamine repeat, which is consistent with the reduced number 
of glutamines identified in other species.  Some domains were conserved in zebrafish and 
show 100% similarity (Fig. 16).  The conservation of these domains serves as evidence 
that the full-length rai1 clone from zebrafish in our study is truly the ortholog of human 
RAI1. 
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                    10        20        30        40        50          
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      mqsfrercgfhgkqqnyqqtsqetsrlenyrqpsqaglscdrqrllakdy  
zebrafish rai1  MQSFRERSGFHSDQHCYQQEPQELPRLESYRHHYSQSRQGYEPHALASAG  
       
 
                         60        70        80        90       100         
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      ynpqpypsyeggagtpsgtaaavaadkyhrgskalptqqglqgrpafpgy  
zebrafish rai1  MSTAGSKDCYGQQNYPVYTSATQTKKPYRGGKTPNQHLQAGYSNHMGTGY  
 
 
                        110       120       130       140       150     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      gvqdsspypgryageeslqawgapqppppqpqplpagvakydenlmkkta  
zebrafish rai1  TAQYMSEGHLQQKWDESAQMTQFEQDMVGRLESGSSQYLEQNMLAISQSQ  
 
 
                        160       170       180       190       200     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      vppsrqyaeqgaqvpfrthslhvqqppppqqplaypklqrqklqndiasp  
zebrafish rai1  CHLPAQSSAPVYTSPHQQGIPPNPAPSPLMYPQGHMHFPQHSQTSSSPSS  
                     
 
                        210       220       230       240       250     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      lpfpqgthfpqhsqsfptsstysssvqgggqgahsyksctaptaqphdrp  
zebrafish rai1  AYMDKCNTASHGYKGYGIPPNAQYGRQLSNHSSLKQSGYRPQNNYGYQQT  
 
 
                        260       270       280       290       300     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      ltassslapgqrvqnlhayqsgrlsydqqqqqqqqqqqqqqalqsrhhaq  
zebrafish rai1  PSRSGFEQGSLQGMSGTQESLQKFQYYNQTQQNYCITDISVRSPEQYYQT  
 
                 
                        310       320       330       340       350     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      etlhyqnlakyqhygqqgqgycqpdaavrtpeqyyqtfspssshsparsv  
zebrafish rai1  CSPSSSHSPARSVGRSPSYNSTPSPLMANADSFQYGQPPINPGASSSTGL  
 
        
                        360       370       380       390       400     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      grspsysstpsplmpnlenfpysqqplstgafpagitdhshfmpllnpsp  
zebrafish rai1  QNEQNMLMPPHTHSSSSVNQTQSFSGSMKERFSEKLLTNPSLWSLNALTS 
 
         
                        410       420       430       440       450     
 
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      tdatssvdtqagnckplqkdklpenllsdlslqsltaltsqvenisntvq  
zebrafish rai1  QVENISNNVQQLLLSEALMASKKTSKRNHPKKGEDYRGQLEGMDESCPEN  
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                        460       470       480       490       500     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      qlllskaavpqkkgvknlvsrtpeqhksqhcspegsgysaepagtplsep  
zebrafish rai1  QHGPSPSDAYSIPRSMTAGLQEGGYSSSTEDQMERNYYYFGQEKGQGHTQ  
 
 
                        510       520       530       540       550     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      psstpqsthaepqeadylsgsedplersflycnqargsparvnsnskakp  
zebrafish rai1  THSRLSLDTVSTCSLNSADDVSVRSGDSVRSLQSVASEDNLNCDPRVQRA  
 
            
                        560       570       580       590       600     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      esvstcsvtspddmstksddsfqslhgslpldsfskfvagerdcprllls  
zebrafish rai1  LSEEEPDSSLCCIRDERSPIGVTAPSPMKQESDSPPDIKRSESTQKENFE  
 
 
                        610       620       630       640       650     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      alaqedlaseilglqeaigekadkawaeapslvkdsskppfslenhsacl  
zebrafish rai1  ESAWTERMADEDKTEQSKPSAEHDCKGEVTEKQEKWLEDEKGPALFQKIN  
 
 
                        660       670       680       690       700     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      dsvaksawprpgepealpdslqldkggnakdfspglfedpsvafatpdpk  
zebrafish rai1  KTVLEEGYSYETEENIYQGLQNKYDSEKENTTEIDCFAELNHKCDEDTEI  
 
 
                        710       720       730       740       750     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      kttgplsfgtkptlgvpapdpttaafdcfpdttaassadsanpfawpeen  
zebrafish rai1  KTEHFKSEPQTSVEMPTEDSPSNSATELCLPEKEEHSSSENSVETPTCTL  
 
 
                        760       770       780       790       800     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      lgdacprwglhpgeltkgleqggkasdgiskgdtheasaclgfqeedppg  
zebrafish rai1  EGPADTLEEQTSVLSHTSTEVGDEKDSILTSSEEVINNKTESQESFPDVC  
 
 
                        810       820       830       840       850     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      ekvaslpgdfkqeevggvkeeaggllqcpevakadrwledsrhccstadf  
zebrafish rai1  GTYEEAENMQQVNTETAESIAQDTPHRDSERRSVICDIAPQTHTAKSDFS  
 
 
                        860       870       880       890       900     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      gdlpllpptsrkedleaeeeysslcellgspeqrpgmqdplspkaplict  
zebrafish rai1  ALNEKTTPLAQARDHHIDCSDAKVLEPDSPQLPGKSILHSAPSWADTPPS  
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                        910       920       930       940       950     
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      keeveevldskagwgspchlsgesvillgptvgteskvqswfesslshmk  
zebrafish rai1  PKKADEDMEPGINCPSAVTPSAKPEAFTPSSHTRMFGKKHVRGRRRPMSS  
 
 
                        960       970       980       990       1000    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      pgeegpdgerapgdsttsdaslaqkpnkpavpeapiakkepvprgkslrs  
zebrafish rai1  TAGIRRQLSIEGDTQTPNIPSSKTTDIVDQMETAHQNVSSQTPKLVTESL  
 
 
                        1010      1020      1030      1040      1050    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      rrvhrglpeaedspcrapvlpkdlllpesctgppqgqmegagapgrgase  
zebrafish rai1  PSRMCTRSYGSQGSPKVSPQDRRKPGAKPAPKPSSKIAVKPGPKSNPKPA       
 
                 1060      1070      1080      1090      1100    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      glprmctrsltalseprtpgppgltttpappdklggkqraafksgkrvgk 
zebrafish rai1  PKHSPKSITKPGSKSVPKSEVMPSVKPGPKPGLKSTGSKESPKPCPKSGP  
 
 
                        1110      1120      1130      1140      1150    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      pspkaasspsnpaalpvasdsspmgsktketdspstpgkdqrsmilrsrt  
zebrafish rai1  KSATKSGPKTASKPASKPGSVPGEILAPKSNQNTAESKPIVASVAKGPGR  
 
 
                        1160      1170      1180      1190      1200    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      ktqeifhskrrrpsegrlpncratkklldnshlpatfkvssspqkegrvs  
zebrafish rai1  PKGISKNKQMKMKQDENVQTTTEHTKDTHCTQELNLQDVTTELALDTIVG  
 
 
                        1210      1220      1230      1240      1250    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      qrarvpkpgagsklsdrplhalkrksafmapvptkkrnlvlrsrsssssn  
zebrafish rai1  VVDTTKGETVAPTLECTLDSSCLKSLGREQKSMVLRSRKQTKEKLTEEKE  
 
 
                        1260      1270      1280      1290      1300    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      asgnggdgkeerpegsptlfkrmsspkkakptkgngepatklpppetpda  
zebrafish rai1  QNDDKSTKTPSAMVMQDVTVDQSCKTGPSNLELPKQKDVSTDSLQQPDEE  
 
 
                        1310      1320      1330      1340      1350    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      clklasraafqgamktkvlpprkgrglkleaivqkitspslkkfackapg  
zebrafish rai1  VVSTKRKCSLPTSETKKRKKGRQDEVKAQDSPLDIVHIPKGKRKRGQRLL  
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                        1360      1370      1380      1390      1400    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      aspgnplspslsdkdrglkgaggspvgveeglvnvgtgqklptsgadplc  
zebrafish rai1  VESVSTTLTTDTLPTDDISDVPSVPPQCPTKTKYLPPRKGRGLKYEAMVQ  
 
 
                        1410      1420      1430      1440      1450    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      rnptnrslkgklmnskklsstdcfkteaftspealqpggtalapkkrsrk  
zebrafish rai1  KITSPGSKKQPVSNQADIALEESTLKPVPQVPDQKETTNAPEMPQKEGES  
 
 
                        1460      1470      1480      1490      1500    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      gragahglskgplekrpylgpallltprdrasgtqgasednsggggkkpk  
zebrafish rai1  TISTQEPENTEIQTPRKKRRKWATVESSDAPDVSLDGGSLIINTPRLAKQ  
 
 
                        1510      1520      1530      1540      1550    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      meelglasqppegrpcqpqtraqkqpghtnyssyskrkrltrgrakntts  
zebrafish rai1  RAIKNNHEMHLKQRKKRRKGTEPQENIPIVEQPESTQTEVLPTSPPPPET  
 
        
                        1560      1570      1580      1590      1600    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      spckgrakrrrqqqvlpldpaepeirlkyissckrlrsdsrtpafspfvr  
zebrafish rai1  LEQTECKEPPNEVCVPLMKPKRGRRPSLKKKQEELSKSQKEDENAIEKKK  
      
                        1610      1620      1630      1640      1650    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      vekrdafttictvvnspgdapkphrkpsssassssssssfsldaagasla  
zebrafish rai1  KTGPKKKCVDAVKVVVKRPKIKTNELSPTVQGTLSDLRPDLSDGKSSVRP  
 
 
                        1660      1670      1680      1690      1700    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      tlpggsilqprpslplsstmhlgpvvskalstsclvcclcqnpanfkdlg  
zebrafish rai1  YVHIDSSMDVASSCTIVNRPEEEQMLAQARTKSVPNIKNQAAKTGSNSSV  
 
        
                        1710      1720      1730      1740      1750    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      dlcgpyypehclpkkkpklkekvrpegtceeaslplertlkgpecaaaat  
zebrafish rai1  MLQGPLVNKSLSDRCLTCCLCGKPANYRELGDLCGPYYPEDCIPRKTLSL   
 
 
        
                        1760      1770      1780      1790      1800    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      agkpprpdgpadpakqgplrtsarglsrrlqscyccdgredggeeaapad  
zebrafish rai1  THRSEFRQNSNCANETESSSIVKNTQSVCEEAIHQEKANEGHSRRSKRAI  
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                        1810      1820      1830      1840      1850    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      kgrkhecskeapaepggeaqehwvheacavwtggvylvagklfglqeamk  
zebrafish rai1  RELSRTRPSSRMRFKRLLILQSRLSGASPPAGVEGIETSLQRLQMEAEEK 
  
       
                        1860      1870      1880      1890      1900    
                ....|....|....|....|....|....|....|....|....|....| 
HUMAN RAI1      vavdmmcsscqeagatigcchkgclhtyhypcasdagcifieenfslkcp  
zebrafish rai1  EHWAHEACAVWTTGIVLVADKLFGLTEAVQKAAHAKCSGCQGEGASVCCG  
               
 
                        1910      1920      1930        
                ....|....|....|....|....|....|....| 
HUMAN RAI1      khkrlp                               
zebrafish rai1  WKSCTQSYHYICAKESGCTFEEETFSIRCPKHKVS  
             
 
 
 
Fig. 16.  Alignment of human and zebrafish RAI1/rai1 amino acids.  Like 
human RAI1, zebrafish rai1 contains nuclear localization signals, a PHD domain, 
and poly serine domains, and shows similarity to TCF20.  Zebrafish rai1 is 
composed of many amino-acid domains that are conserved in human and share 
100% similarity.  These amino-acids sequences can be acting as regulatory factor 
for normal RAI1 functioning and their conserved nature helps in aligning the 
protein.  The conservation of the domains between human and zebrafish strongly 
suggest that this clone is an ortholog of human RAI1. 
 
List of Domains (% identity to human)    
Similarity to TCF20 – MQSFRER (100%)        
Glutamine region – QQ (Human RAI1 typically carries 13 Q‘s, while mouse carries 4) 
Nuclear localization signal (3) -  KKRKKGRQDEVKAQDSPLDIVHIPKGKRK 
       KKRRK 
                       KKKQEELSKSQKEDENAIEKKK 
Polyserine domain – SPSSSHSPARSVGRSPSYNSTPSPLM (100%) 
PHD domain – KCSGCQGEGASVCCGWKSCTQSYHYICAKESGCTFEEETFSIRCPKHK (24%) 
Conserved domain - HFPQHSQ (100%) 
Conserved domain - PEQYYQT (100%) 
Conserved domain –ALTSQVENIS (100%) 
Conserved domain – VQQLLLS (100%) 
Conserved domain – VSTCS (100%) 
Conserved domain – LCGPYYPE (100%) 
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CHAPTER 4: Spatial and temporal rai1 expression in zebrafish 
embryos 
 
 
Introduction 
 In order to understand the dosage-sensitive role of rai1 gene and its effect on 
complex phenotypes, it is important to evaluate the zebrafish model that is 
overexpressing or deficient in rai1 and compare the result with wild-type zebrafish with 
normal levels of rai1. In humans, RAI1 mRNA is generally expressed in all tissues but 
present at high levels in heart and neuronal structures (40, 46).  Similarly in mouse, 
immunohistochemistry (IHC) with a Rai1 antibody detected expression mainly in 
cerebral cortex, cerebral hemisphere, ganglion, thymus, and midbrain (Fig. 17).  
Preliminary data from zebrafish studies show rai1 expression in the lens, midbrain, and 
diencephalon.  A complete spatial and temporal profile of rai1expression will facilitate 
the background for evaluating the changes in gene expression and morphology in the 
presence of altered levels of rai1.   
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Cerebral cortex Midbrain 
Cerebral 
hemisphere 
Ganglion 
Thymus 
 
 
                                              
       18 dpc        72 hpf 
IHC with Rai1 ab      ISH with rai1 probe 
                                                                                              
Fig. 17.  rai1 expression in mouse vs. zebrafish.  As in mouse, zebrafish show 
widespread rai1 expression during embryonic development. Expression in both species 
becomes more specific in certain areas, especially in the brain. The expression in mouse 
is detected in the cerebral cortex, ganglion, thymus, and midbrain (Girirajan Dissertation, 
2008).  The expression in zebrafish is detected in similar regions including midbrain, 
forebrain and diencephalon. 
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Materials and methods 
Zebrafish culture and maintenance 
Zebrafish lines 
Wild-type adult fish of AB strain were used for the experiments. 
Aquarium system 
Zebrafish were maintained in recirculating system water with the 500 µS as the 
parameter of conductivity, 27-28°C as the temperature, optimum chemical and biological 
pressure, UV sterilization, and pH of 7.  For breeding, approximately 8 adult fish were 
placed in 3.0 liter tanks. 
 
Early stages - (<2.5 hpf, 9 hpf, 15hpf and 18hpf) 
Collect cultivated embryos  
 Embryos were harvested and collected as described in Chapter 3. 
 TRizol treatment  
Collected embryos were incubated at 28.5°C until they reached the required stage. 
At the various stages such as <2.5 hpf, 9 hpf, 15 hpf and 18 hpf, a total of 30 embryos 
were homogenized in 1 ml of TRizol reagent and stored at -20°C until ready to isolate 
RNA. 
 RNA extraction  
 Total RNA was extracted from the trizol treated embryos using the RNA 
preparation kit (Invitrogen), according to the manufacturer‘s instructions. 
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Reverse-transcriptase PCR (RT-PCR) 
 First strand cDNA synthesis was performed as described in Chapter 3. 
Semi-quantitative PCR 
 cDNA obtained from  <2.5, 9, 15 and 18 hpf embryos was PCR amplified with 
internal control (TCOF1- like gene) primers [F (gcgatctctaccaacatgtg) and R 
(cttggctgatgggccattga)].  rai1 was then PCR amplified with primers in the exon 3 region 
[rai1F (agggcactgtctgaagagga) and rai1R (ttggcagtgtgagtctgagg)], followed by PCR 
amplification using primers spanning the exonic boundary of rai1 exon 2 and 3 [SHE646 
(gcgcccagatctaagtgacg) and SHE650 (tcacacacttaccttgtgtttcgg).  PCR reaction mix and 
conditions were followed as described in Chapter 2 (Polymerase chain reaction).  PCR 
products were evaluated by gel electrophoresis. 
 
Later stages - (24, 30, 31, 35, 37, 48 and 72 hpf) 
Collect cultivated embryos  
 Embryos were harvested as described in Chapter 3.  There were a few exceptions 
to the previous protocol, including the addition of 2 µl of methylene blue for fungus 
prevention and 500 µl of 0.12% of 1-phenyl-2-thiourea (PTU) to inhibit pigmentation, in 
each petri dish with ~ 80 embryos and then incubated at 28.5°C. 
Probe preparation 
 A glycerol stock of the plasmid containing the 5‘ end (exon 1) of zebrafish rai1 
gene (Fig. 18) was used to grow colonies for DNA isolation.  DNA was extracted using 
the mini kit by Qiagen (Valencia, California, USA), according to the manufacturer‘s 
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protocol.  The isolated DNA was quantified by a spectrophotometer. The DNA template 
was linearized by digesting 5 µg, overnight at 37° C with BamHI enzyme (anti-sense 
probe) and with NotI enzyme (sense probe).  After the enzyme digest, the DNA/probe 
was purified from the solution using the ultraclean kit by Molecular Biology labs 
(Carlsbad, CA).  DNA was then quantified by a spectrophotometer.  This was followed 
by a transcription reaction containing 8 µl of nuclease-free water, 4 µl of transcription 
buffer (5X), 2 µl of DIG-NTP mix (10X), 1 µl of RNA polymerase (T7 - antisense probe 
and SP6 – sense probe), 1 µl of RNasin and 1 µg of linearized DNA templates, all 
assembled in order and incubated at 37°C (antisense probe) and 40°C (sense probe) for 2 
hours.  This was followed by the addition of 1 µl of RNase-free DNase I after the 
transcription reaction and incubation at 37°C for 15 mins.  Finally, the digoxigenin-
labeled probe was purified by using Probe Quant G-50 micro column purification kit by 
Illustra
TM 
(Buckinghamshire, UK) and 80 µl of hybridization buffer [50% formamide, 5X 
sodium citrate buffer (SSC), 50 µg/ml heparin, 0.5 mg/ml yeast tRNA, 0.1% tween-20, 
9.2 mM of citric acid, and nuclease-free water] was added to the purified probe and 
stored at -20°C. The probe sequence was aligned with the putative rai1 gene and it was 
found to be identical to the 5‘ end (beginning of exon 1) of the rai1 gene (Fig. 18 and 
19). 
In-situ hybridization  
 As mentioned earlier, embryos were incubated at 28.5°C until they reach the 
required stage.  At these stages, ~ 30 embryos were dechorionated and anesthetized by 
addition of  20 µl of MESAB before they were fixed in 4% of paraformaldehyde (PFA) 
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for overnight on the shaker.  Next day, PFA solution was replaced with methanol and the 
embryos were stored at -20°C for overnight.  The embryos were then rehydrated through 
methanol/PBT series washes (100%: 0%, 66%: 33%, 33%: 66% and 0% : 100%) for 5 
mins on the shaker.  These washes were followed with Proteinase K (PK) treatment: 1 µl 
of PK in 1 ml of PBT for 2.4 mins for 24 hpf embryos and 4.8 mins for 48 hpf embryos 
and so on.  This was followed by aspiration of PK solution and post-fixation of the 
embryos with 4% PFA on the shaker for 20 mins.  After post-fixation, the embryos were 
washed several times with PBT and then incubated in Hyb (+) for > 1 hour in water bath 
set at 65°C.  The solution was replaced with diluted probe (1:200) in Hyb (+) and 
incubated overnight at 65°C.  Next day, the diluted probe solution was aspirated and 
saved for re-use.  It was replaced by (Hyb -) buffer [hybridization buffer without tRNA 
and heparin] for a quick wash followed by series of Hyb (-)/ 2 X SSC series (66% :33%, 
33%: 66%, 0%: 100%) for 10 mins at 65°C, and two 20 mins washes of 0.2 X SSC at 
65°C.  This was followed by three serial washes of 0.2XSSC/PBT (66%: 33%, 33%:66%, 
0%:100%) for 5 mins on the shaker.  Embryos were then treated with blocking solution 
[1X PBT, 2 mg/ml bovine serum albumen (BSA), and 2% goat serum (GS)] for 1 hour on the 
shaker.  This blocking solution was replaced with alkaline-phosphatase-coupled anti-
digoxigenin FAB fragments diluted (1:10,000) in blocking solution and incubated overnight 
at 4°C.  On day 5, embryos were washed five times with PBT for 15 mins on the shaker.  
This was followed with three washes of coloration buffer [0.1 M Tris hydrochloride (pH 9.5), 
50 mM MgCl2, 0.1 M NaCl and dH20] with 0.1% Tween 20 for 5 mins on the shaker.  After 
these washes, the solution was replaced with nitro blue tetrazolium [NBT] [225 μg/ml] and 
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bromo-4-chloro-3-indolyl phosphate [BCIP] added in coloration buffer with Tween, and the 
embryos were kept in the dark box on the shaker during the day and incubated  at 4°C during 
the night for two consecutive days.  When the embryos were stained sufficiently, the 
coloration buffer was aspirated and the embryos were given a quick PBT wash.  The embryos 
were then dehydrated with methanol for ~ 20 mins on the shaker to clear out the background.  
Before performing the imaging, the embryos were rehydrated through a methanol/PBT series 
and equilibrated in 1X PBS with 50% glycerol.  All pictures were taken with an Olympus 
SZX12 microscope and Olympus DP70 camera using an 80X objective lens. 
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I 
probe 
 
 
 
 
 
 
 
 
 
rai1 
              5824 bp 
 
Fig. 18.  Schematic representation of the ISH probe.  Probe maps to the 5‘end of the 
exon 1 region of the putative rai1 gene.  
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60        70        80        90       100           
....|....|....|....|....|....|....|....|....|....| 
SP6            ctagtaacggccgccagtgtgctggaattcgccct---tgaattccacca  
putative rai1  --------------------------------cctatctggagtc----a  
 
                       110       120       130       140       150     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            tgcagtccttcagagagcggagtggtttccatagcaaccagcactgctac  
putative rai1  tgcagtccttcagagagcggagtggtttccatagcaaccagcactgctac  
 
                       160       170       180       190       200     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            cagcaggaaccccaagaattaccgcgcctcgagagctacagacatcatta  
putative rai1  cagcaggaaccccaagaattaccgcgcctcgagagctacagacatcatta  
 
                       210       220       230       240       250     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            cagccagtccagacagggctacgagccacacgctttagcttctgccggga  
putative rai1  cagccagtccagacagggctacgagccacacgctttagcttctgccggga  
 
                       260       270       280       290       300     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            tgtcaacagcgggatctaaagactgttacggacagcagaactatcctgtc  
putative rai1  tgtcaacagcgggatctaaagactgttacggacagcagaactatcctgtc  
 
                       310       320       330       340       350     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            tacaccagcgccacacagactaagaaaccatacagaggaggcaaaactcc  
putative rai1  tacaccagcgccacacagactaagaaaccatacagaggaggcaaaactcc  
 
                       360       370       380       390       400     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            aaaccagcatctgcaggcgggctacagtaaccacatgggcaccggataca  
putative rai1  aaaccagcatctgcaggcgggctacagtaaccacatgggcaccggataca  
 
                       410       420       430       440       450     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            cggcccagtacatgagcgaaggtcacctgcagcagaaatgggatgagtcg  
putative rai1  cggcccagtacatgagcgaaggtcacctgcagcagaaatgggatgagtcg  
 
                       460       470       480       490       500     
               ....|....|....|....|....|....|....|....|....|....| 
SP6            gctcagatgacccagttcgagcaggacatggtgggtcgtctggagtctgg  
putative rai1  gctcagatgacccagttcgagcaggacatggtgggtcgtctggagtctgg  
 
Fig. 19. Alignment of the ISH probe with the rai1 gene sequence. The anti-sense 
probe was sequenced with the SP6 primer.  This sequence when aligned with the putative 
rai1 gene, is identical to the 5‘ end (beginning of transcription in exon 1-- ATG) of the 
rai1 gene. 
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Results 
rai1 expression detected at early stages 
 Gel electrophoresis results from rai1 RT-PCR from <2.5 hpf, 9 hpf, 15 hpf, and 
18 hpf zebrafish embryos is shown in Fig. 19.  Internal control (TCOF1- like gene) 
spanning the exonic region showed expression at all stages verifying  the good quality of 
the cDNA.  RT-PCR analysis detected rai1 gene expression during early zebrafish 
embryogenesis at 9, 15 and 18 hpf.  A maternal rai1 transcript (< 2.5 hpf) was not 
detectable/present in early embryonic development.  
 
 
Fig. 20.  RT-PCR showing rai1 expression at early stages. Internal control (TCOF1-
like gene) shows expression at all stages (yellow). rai1 expression is detected at 9 hpf, 15 
hpf and 18 hpf but not at < 2.5 hpf, using specific primers spanning rai1 exonic region 
(blue). 
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rai1 expression patterns at later stages 
 
The rai1 expression patterns observed in zebrafish embryos was similar to the 
known Rai1expression patterns seen in mouse at corresponding developmental stages 
(Fig. 17).  As in mouse, zebrafish embryos showed widespread rai1 expression during 
embryonic development, especially in the brain and neuronal areas as shown by ISH.  
The spatial and temporal profile of zebrafish rai1 expression is shown in Fig. 21.  At 24- 
30 hpf, rai1 expression was detected everywhere in the embryos, particularly in the 
forebrain and diencephalon.  As the developmental stage progressed, the expression 
became more specific in the forebrain, midbrain and diencephalon.  The rai1 expression 
observed in the lens of the embryos was an artifact as indicated by the similar expression 
detected in the control embryos.   
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24 hpf 30 hpf 31 hpf 
(a) 
(b) 
(Anti-sense) Diencephalon 
Forebrain 
Midbrain 
Fig. 21.  Spatial and temporal profile of rai1 expression. (a,c) rai1 expression was detected throughout the embryo at 24-30 
hpf. Expression became more specific to the brain regions including midbrain, forebrain, and diencephalon from 31 hpf 
onwards and was observed in the brain through 72 hpf. (b,d) No expression detected in control embryos. Expression in the lens 
was an artifact, as similar expression was also detected in the control embryo. 
 
      
 
 
   
  Control 
48 hpf 37 hpf 
(Sense) 
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Discussion 
Spatial and temporal profile of rai1 expression 
 rai1 expression was detected by reverse transcriptase  polymerase chain reaction 
(RT-PCR) and whole-mount in-situ hybridization (ISH) in developing zebrafish embryos 
in tissue-dependent and time-dependent fashion.  RT-PCR detected rai1 expression at 9 
hpf, 15 hpf and 18 hpf (Fig. 20).  Maternal expression (< 2.5 hpf) was not 
detected/present in early embryonic development.  ISH detected rai1 expression in 
zebrafish embryos at different developmental stages (24-72 hpf).  Although the 
expression was present throughout the embryo at 24 hpf; it became more restricted with 
the progressing developmental stage (~ 35 hpf).  The expression was specific in neural 
tube and brain regions such as diencephalon, midbrain and forebrain as shown in the Fig. 
21.  But the expression became localized specifically to the brain regions in later stages 
(~ 48 hpf).  The expression observed in the lens was an artifact as seen by similar 
expression in the control embryos.  The completed spatial and temporal profile of normal 
rai1 expression established the background necessary to monitor changes in morphology 
and gene expression associated with rai1 response to RA treatment. 
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CHAPTER 5: rai1 expression in response to retinoic acid 
 
 
Introduction  
 Previous studies have shown RAI1 as the primary gene underlying the SMS 
phenotype, and its haploinsufficiency causes SMS (10).  Patients with SMS exhibit 
craniofacial abnormalities, behavioral abnormalities, sleep problems, developmental 
delay and other manifestations.  This suggests that RAI1 gene dosage is critical for 
normal growth, development and behavior.  Hence, it was important to investigate the 
factors playing a role in regulating RAI1 gene dosage and expression. 
Retinoic acid 
 In 1995, Imai et al had shown the upregulation of the Rai1 gene in mouse P19 
cells in response to the induction by RA and RA had led to differentiation of the neurons 
(26).  This suggested an indirect role played by RA in causing SMS phenotype.  In 
addition to this, many other studies (14, 25) have shown the dosage effects of exogenous 
RA resulting in craniofacial anomalies in both mouse (28) and zebrafish embryos (9) and 
human.   To further investigate the effects of RA concentrations on rai1 expression and 
zebrafish development, zebrafish embryos were treated with varying concentrations of 
RA, and the rai1 expression and morphology was compared to the wild-type embryos 
with normal rai1 expression.  
   
79 
 
4-Diethylaminobenzaldehyde 
Diethyaminobenzaldehyde (DEAB) is an inhibitor of retinaldehyde 
dehydrogenases 2 (41, 42) and prevents the production of RA. Assessing the rai1 
expression in the absence of RA helped in determining the overall impact of RA on rai1 
gene expression.  
 
Materials and methods 
Preparation of RA and DEAB 
 All-trans RA was obtained in powder form (Sigma) and RA stocks were made in 
ethanol at 200 µM concentration.  The stock was diluted to 4 µM/ 20 uM in DMSO and 
then 10 µl of this working stock (4 µM /20 µM/) + 10 µl of DMSO was added to 20 ml of 
embryo medium to make the final concentration of RA to 2 nM/10 nM.  Similarly, 
DEAB (Sigma) stocks were made in ethanol at 100 mM concentration and diluted to 10 
mM in DMSO. Then, 10 µl of this working stock (10 mM) + 10 µl of DMSO was added 
to 20 ml of embryo medium to make the final concentration of DEAB at 5µM.  For the 
combined treatment of RA + DEAB, 10 µl of RA (4 µM/20 µM) + 10 µl of DEAB (10 
mM) was added to 20 ml of embryo medium. Compounds were added at various 
timepoints to determine the critical period of responsiveness.  
Collect cultivated embryos 
 Embryos were harvested and collected as described in Chapter 3.  There were a 
few exceptions to the previous protocol, including the addition of RA (2 nM/10 nM) 
only, DEAB (5 µM) only , RA (2 nM /10 nM) + DEAB (5 uM) and DMSO (control) in 
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20 ml of embryos medium (1X) instead of water in each petri dish with ~ 80 embryos.  
This was followed by 2 µl of methylene blue to prevent fungus growth and 500 µl of 
0.12% of 1-phenyl-2-thiourea (PTU) to inhibit pigmentation, in each petri dish and then 
incubated at 28.5°C. 
Experimental set-ups 
 Three different experimental set-ups were arranged to investigate the effect of 
half-life of RA and DEAB on the developing embryos.  Eight petri dishes were set-up 
with ~ 80 embryos in each of them, and four of them contained embryo medium with RA 
(only)/DEAB (only)/RA+DEAB (both) and DMSO  (control) along with methylene and 
PTU.  In the first set-up, embryos were treated with RA and DEAB only once at 8 hpf. 
The second experimental set-up contained embryos treated with higher concentration of 
RA at 10 nM instead of RA at 2 nM on first day (8 hpf), while the third set-up had two 
different set of groups. The first group of embryos were treated once at 8 hpf while the 
other group of embryos has the treatment changed on first (8 hpf) as well as second day 
(27 hpf).  
In-situ hybridization 
 Refer to the protocol described in Chapter 4. 
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Fig 22. Experimental set-ups to investigate the effect of RA and DEAB on embryos. 
Embryos were treated with RA/DEAB/RA+DEAB treatment at different time points. 
 
Results 
Effect of RA on rai1 expression 
 Treatment of zebrafish embryos at 24 hpf with 2 nM RA expanded expression of 
rai1 throughout the nervous system (Fig. 23).  Treatment of 48 hpf embryos with the 
same concentration of RA (2 nM) induced expression similar to previous stages, but was 
more specific to the forebrain, midbrain, and diencephalon.  Treatment at the same stage 
(48 hpf) as well as 30 hpf and 72 hpf, with 5-fold higher concentration of RA (10 nM) 
demonstrated the variable response of the rai1 expression (Fig. 24).  For example, the 
expression was much higher in specific regions including diencephalon, midbrain, and 
forebrain.  Similar results were observed in embryos treated twice with RA (2 nM/10 
nM) at different timepoints (Fig. 25).  Hence, in the presence of exogenous RA, rai1 
expression is induced in a non-specific manner throughout the embryo at 24 hpf but 
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becomes higher and specific by 48 hpf.  Hence, rai1 is regulated by RA in a tissue and 
time specific manner.  
 
Effect of DEAB on rai1 expression 
 Compared to untreated zebrafish embryo (DMSO), DEAB (5 µM)  treated 
embryos at 24 hpf, 30 hpf , 48 hpf and 72 hpf had a significant reduction of the rai1 
expression in the trunk (spinal cord), but the expression remained high in brain regions 
(Fig. 23 and 24).  Similar results were observed in embryos treated twice with DEAB at 
different time points (Fig 25).  These embryos were deformed with shortened hindbrains, 
slightly rounded somites, shortened and curved body axes, inflated yolk sac and mild 
cardiac edema.  
 
RA + DEAB counteract each other 
 The zebrafish embryos were also treated with the combination of RA (2 nM/ 10 
nM) + DEAB (5 µM). The rai1 expression in these embryos at 24 hpf, 30 hpf, 48 hpf and 
72 hpf was similar to rai1 expression observed in the DMSO treated (control) embryos 
(Fig. 23 and 24). Similar results were observed in embryos treated twice with RA + 
DEAB at different timepoints (Fig. 25). 
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Fig. 23.  Effect of RA (2 nM) and DEAB (5 µM) on zebrafish embryos.  RA induces rai1 expression throughout the  
   embryos at 24 hpf and becomes specific to the brain regions by 48 hpf. DEAB reduces expression in the neural tube 
    but it remains high in the brain regions. RA + DEAB counteracts each other and expression is similar to DMSO. 
                          
 
 
 
 
 
 
 
 
 
24 hpf 
48 hpf 
   
84 
 
 
Fig. 24.  Effect of RA (10 nM) and DEAB (5 µM) on zebrafish embryos. rai1 expression is similar to Fig. 23. 
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Fig. 25.  Effect of RA (10 nM) and DEAB (5 µM) on zebrafish embryos. rai1 expression is similar to Fig. 23.
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Discussion 
RA is not solely responsible in inducing rai1 expression 
 Expression of rai1 in response to the presence or absence of retinoic acid at two 
different concentrations was assessed in the developing zebrafish embryos (Fig. 23 and 
Fig. 24).  Retinoic acid (RA) is a derivative of vitamin A and has been shown to induce 
the upregulation of the rai1 gene in cultured cells.  On the other hand, diethylaminobenz-
aldehyde (DEAB) is an inhibitor of retinaldehyde dehydrogenases and stops the 
production of RA.  Deprivation of RA leads to craniofacial anomalies as shown in 
previous studies (9, 14, 25, 28).  In our study, DMSO treated embryos served as the 
control for normal rai1 expression.  ISH results from 24 hpf and 48 hpf indicated that RA 
treatment at 2 nM concentration induced rai1 expression throughout the embryo as 
compared to the DMSO treated embryos (Fig. 23). Similar results were also observed in 
embryo at 30 hpf, 48 hpf and 72 hpf stages when treated with higher concentration of RA 
(10 nM) (Fig. 24).  DEAB treatment at 5 µM concentration reduced the rai1 expression 
in the trunk (spinal cord) but the expression remained high in the brain region (Fig. 23 
and 24).  However, these embryos were greatly deformed with shortened hindbrains and 
faces, slightly rounded somites, shortened and curved body axes, inflated yolk sac and 
also displayed mild cardiac edema and were difficult to study.  The combination of RA 
and DEAB treatments counteracted each other, and the rai1 expression was similar to the 
DMSO treated embryos.  Similar results were observed in embryos treated twice with 
RA/DEAB or RA + DEAB at different timepoints (Fig 25).  Due to the fact that DEAB 
treatment inhibited RA but did not take away the rai1 expression throughout the embryo, 
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it suggests that RA is not solely responsible for rai1 expression at the developmental 
stages studied by ISH.  Further studies assessing rai1 expression at the cellular level 
should be performed to investigate if rai1 expression in response to RA is cell-type 
specific. 
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CHAPTER 6: Discussion 
 
 
 
RAI1/rai1 gene dosage effects in humans and zebrafish 
 Genetic syndromes such as Prader-Willi, Williams, Down, and Fragile X are 
complex disorders involving dysregulation of several developmental process that 
maintain normal growth and behavior.  Smith-Magenis syndrome is a complex 
neurobehavioral disorder caused by a 17p11.2 deletion or a mutation in the RAI1 gene.  
Cases with 17p11.2 deletions always have a deletion of RAI1 gene.  However, the 
mutation cases have a single base change or microdeletion in the RAI1 gene that causes 
SMS.  Phenotypic comparison between the 17p11.2 deletion and mutation cases indicates 
that haploinsufficiency of the RAI1 gene is responsible for causing SMS features (15).  
Previous studies in mouse P19 cells have shown that RA induces the Rai1 gene (26).  
Taken together, these data suggest that RAI1 gene dosage is vital for normal development 
and behavior.  Zebrafish is an excellent model system to study dosage-sensitivity of the 
rai1 gene.  Using zebrafish as a model, we cloned zebrafish rai1 gene, evaluated the 
spatial and temporal profile of rai1 expression and investigated the role of RA on rai1 
expression.  Results from this study show the rai1 gene was expressed in a time-
dependent and tissue-dependent manner and RA was not solely responsible for inducing 
   
89 
 
rai1 gene expression.  It seems like there are several factors/pathways regulating the 
expression and function of rai1 gene.   Future experiments exploring the factors 
regulating the rai1 gene and the required rai1 dosage threshold for normal growth, 
development and behavior are necessary to increase our understanding of this gene.  The 
results from these studies will facilitate insight about treatment options that can alleviate 
some of the phenotypic SMS features and prevent the morbidity associated with this 
syndrome. 
Future studies 
Future research on SMS and the rai1 gene using the zebrafish model could include 
creating a rai1 antisense morpholino to perform knockdown, or overexpression studies.  
This will be achieved if the cells are prevented from making rai1 protein or make the 
protein in excess.  If this knockdown or overexpression causes developmental problems, 
we can learn about the function of rai1 protein and its role in the developmental process.  
We can use the rai1 full length clone to perform rescue experiments to show that the 
phenotype of any knockdown is specific to rai1.  This will determine the contribution of 
the rai1 gene to any phenotypic features observed with knockdown of rai1 in zebrafish.  
Additionally, we can investigate upstream and downstream effects of rai1 RNAi 
knockdown on other candidate genes.  Microarray analysis data obtained from RAI1-
RNAi knockdown cell lines and cells overexpressing RAI1 revealed a defined group of 
genes that had their expression increased or decreased in response to RAI1 suppression 
(Girirajan et al., 2008).  First, we need to determine if these genes are present in the 
zebrafish genome and then evaluate how these genes are regulated in the absence or 
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presence of rai1 in zebrafish.  In short, the zebrafish model is an ideal system for 
investigating pertinent questions regarding the molecular and biochemical pathology of 
SMS and RAI1 gene. 
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APPENDIX A 
 
 
Refined protocol for RAI1 mutation screening 
 
 
 
 
 
1. Run PCRs with RAI1 specific primers. (Refer to Table 1) 
 
PCR Reaction Mix: 
 
 2.5 μl 10x PCR buffer 
 0.5 μl 10 mM dNTPs 
 0.5 μl 20 μM forward primer 
 0.5 μl 20 μM reverse primer 
 0.25 μl Taq (5U/μl) 
 4 μl BSA (1 mg/ml) – {except SHE345/664} 
 15.75 μl dH2O 
 1.0 μl genomic DNA (~ 50 ng/μl)  DNA must be added at the END 
 
Total Volume: 25 μl (per reaction) 
 
Cycling Conditions: 
 
94 °C 5 min  
   
94 °C 1 min 
35 cycles (Ta – Refer to Table 1) 
Ta 1 min 
72 °C 
1 min (~ 1 Kb product) 
2 min (~ 2 Kb product) 
   
72 °C 10 min  
4 °C indefinite  
 
2. Gel Electrophoresis 
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 Make a 1% agarose gel.  
o Weigh out 0.30 g agarose. 
o Combine agarose and 30 mL TBE Buffer in an Erlenmeyer flask. 
o Heat mixture in the microwave in 10 sec increments to completely 
dissolve the agarose. 
o Cool solution by running flask under cold tap water. 
o Add 3 μL ethidium bromide to the flask. Swirl to mix. 
o Pour agarose solution into gel molds. Let gel set; ~ 15 minutes. 
 Run Products 
o Fill electrophoresis chamber with TBE Buffer and place gel in 
center. 
o Add 3 μL of DNA Ladder (Hyperladder II) to well on far left. 
o On a piece of parafilm place 1 μL drops of 5x loading dye. 1 drop 
for each PCR product.  
o Add 4 μL of PCR product to one drop of dye and mix with pipet. 
Load sample in gel. 
o Run gel at 100 V for 30 minutes. 
o Examine gel under UV lamp (11th floor, Sanger Hall) and take a 
picture. 
o If a single clear band is present with the correct length follow-up 
with Step 3: Clean PCR Products. 
o If multiple bands are present perform a gel extraction using the 
Qiagen Gel Extraction Kit and Protocol. Send purified product 
directly for sequencing—these products do not need treatment with 
ExoSAP-IT. 
 
3. Clean PCR Products 
 
 Use a 96-well PCR plate for several reactions. Otherwise, use individual 
PCR tubes. 
 Mix 5 μl PCR product with 2 μl ExoSAP-IT (USB 78200) for a combined 
7 μl reaction volume. 
 Place in thermocycler under these conditions: 
 
 
 
 
 
 
 The PCR product is now ready for use in DNA sequencing. Treated PCR 
product may be stored at -20 °C until required. 
 
4. Send Treated PCR Products to Massey Core Lab for Sequencing 
SAP (PCR Machine – User: Santhosh) 
37 °C 30 min  
80 °C 15 min To inactivate ExoSAP-IT 
4 °C indefinite  
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 Use either 1.5 ml individual microcentrifuge tubes or 96-well plate for 
samples. 
 Tube 1: Add 3 μl dH2O to 7 μl of treated PCR product for a total volume 
of 10 μl to be sent for sequencing.  
 Tube 2: Add 10 μl diluted primer: 8 μl dH2O + 2 μl of 20 μM primer 
(Refer to page 3 for details regarding use of forward and reverse primers) 
 
5. Analyze Sequence Data 
 
 Analyze by comparing patient sequencing results with the normal RAI1 
gene sequence.  Look at sequence quality and for heterozygosity. 
 Blast using ClustalX/Bioedit 
 Provide sequencing data with a summary sheet of results for each 
amplimer and sequencing primer to Dr. Elsea 
 
6. Documentation of Data 
 
 Draft a Report.  (Windows in Lab Office – click on Documents to Elsea 
lab 2009 to Sequencing Reports, and then use the most updated one as a 
template, 2008) 
 Update Database on Mac (Mutation Summary) 
 Mail report to referring geneticist once Dr. Elsea signs and approves final 
report. 
 Attach a copy of report along with the sequences to the patient SMS file 
and file it in the cabinet. 
 
Sequencing Plan for PCR Products 
 
1
st
 Round of Sequencing 
 
Process the following PCR amplicons with the suggested forward (F) and reverse (R) 
primers 
 
 SHE323/508 
o Primers – SHE666 (R), SHE506 (R), SHE507 (F) 
 SHE327/330 
o Primers – SHE328 (R), SHE329 (F) 
 SHE329/332 
o Primers – SHE331 (F) 
 SHE513/514 
o Primers – SHE514 (R) 
 SHE515/516 
o Primers – SHE515 (F) 
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 SHE335/669 
o Primers – SHE336 (R), SHE669 (R) 
 SHE527/528 
o Primers – SHE527 (F) 
 RA46/45 
o Primers – RA46 (F) 
 SHE345/664 
o Primers – SHE664 (R) 
 
**If the 1st round of sequencing does NOT cover the entire region, then follow-up 
with the 2
nd
 round of sequencing. 
 
*You may need to repeat a sequence if the sequence is not clear and readable. 
 
2nd Round of Sequencing 
Send the following PCR products with highlighted primers only 
 SHE505/506 
 SHE507/508 
 SHE325/326 
 SHE509/510 
 SHE511/512 
TABLE 1. RAI1 PRIMERS 
Exon Primers 
Product 
Size 
Annealing 
Temp. (Ta) 
Start E 3 
SHE323: TCTGAGGCAAAAGGAAGTGG 
1816 bp 
62 °C 
 SHE508: CATGTCGTCAGGAGAGGTCA 
E 3 
SHE327: TGTCAAGAACCTCGTGTCCA 
1434 bp 60 °C 
SHE330: AACCAGCTCTGGACCTTTGA 
E 3 
SHE329: TCTCGCTGGAGAACCACAG 
1765 bp 60 °C 
SHE332: ATGAAGGCCGACTTCCTTTT 
E 3 
SHE513: GCTCCAAGACCAAGGAGACA 
910 bp 62 °C 
SHE514: GCCTCGGTTTTGAAACAGTCA 
E 3 
SHE515: GGCCTCTCCTGGTAATCCTC 
1010 bp 64 °C 
SHE516: GCAGCAAACAAGGCAAGAGGT 
End E 3 
SHE335:AAACCGAGGCCTTCACATC 
1490 bp 60 °C 
SHE669: GTGTGACCTGCCTTAGCCAGAT 
E 4 
SHE527: CCAGCCTGTAAAGCTTGAGG 
362 bp 62 °C 
SHE528: GGAATGCCTCATTTCCATGT 
E 5 
RA46: GGAGTGGAGTGGAGTGTGGAGG 
310 bp 64 °C 
RA45: GGACTGTGAAGGAGGTGCGAGG 
E 6 
SHE345: ACTGTGAAGTCCGAGGTCGT 
313 bp 
60 °C + 
Enhancer SHE664: TGGGCAAGAACGCCCT 
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TABLE 2. RAI1 PRIMERS 
Exon Primers Product Size 
Anneal
ing 
Temp. 
(Ta) 
E 3 
SHE323: TCTGAGGCAAAAGGAAGTGG 
770 bp 62 °C 
SHE324: GACTGGGAATGCTGAGGAAA 
E 3 
SHE325: AAAGGCAGAAGCTGCAGAAC 
875 bp 
62/55 
°C  SHE326: CAGTGCTGGCTTTTATGCTG 
E 3 
SHE327: TGTCAAGAACCTCGTGTCCA 
777 bp 60 °C 
SHE328: GGGAAACAGTCAAAAGCTGC 
E 3 
SHE329: TCTCGCTGGAGAACCACAG 
904 bp 59 °C 
SHE330: AACCAGCTCTGGACCTTTGA 
E 3 
SHE331: CACTCATCTGCACCAAGGAG 
1000 bp 60 °C 
SHE332: ATGAAGGCCGACTTCCTTTT 
E 3 
SHE333: CCAAGAAGCTCCTCGACAAC 
763 bp 59 °C 
SHE334: TTCCGGCTCCTCTTCTTAGG 
E 3 
SHE335:AAACCGAGGCCTTCACATC 
964 bp 60 °C 
SHE336: CACACTCGGGACCTTTGAGT 
E 3 
SHE339: CTACCCTGAACACTGCCTCC 
887 bp 60 °C 
SHE340: AGAGGCAATGGAGACAGGAA 
E 6 
SHE345: ACTGTGAAGTCCGAGGTCGT 
766 bp 
60 °C + 
PCR 
Enhanc
er (no 
BSA) 
SHE346: GACTGGAAAGGGGACAAACA 
E 3 
SHE505: CCCGAGTCATGCAGTCTTTT 
925 bp 60 °C 
SHE506: TGGTAATGGAGGGTTTCCTG 
E 3 
SHE507: GGTCCAGAATCTTCATGCCTA 
947 bp 62 °C 
SHE508: CATGTCGTCAGGAGAGGTCA 
E 3 
SHE509: CTGCCAGGGTCAACAGCAAC 
995 bp 64 °C 
SHE510: CTCCTCCTCAGCTTCCAGGT 
E 3 
SHE511: AGGAGGACCTGGAAGCTGAG 
861 bp 66 °C 
SHE512: GTGACCGAAGGATCATGGAGC 
E 6 
SHE663: ACCCCAGCCGCGCTCT 
387 bp 52 °C 
SHE664: TGGGCAAGAACGCCCT 
E 3 SHE666: TGCAGGCCTTGCTGTGT Internal Primer N/A 
E 3 SHE669: GTGTGACCTGCCTTAGCCAGAT Internal Primer N/A 
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APPENDIX B 
 
 
Revised genomic sequence of the RAI1 gene 
 
 
 
 
 
Genomic sequence surrounding RAI1 
 
Exon 3 
 
gcgggggagc aggcagggtg gggaggtggg tgggcgggcg ctttctgagg caaaaggaag SHE323 
tggcccgtct gaatcgctca tcctctgccc cctccctgcc catcctcccc tccctccttc 
cctccctccc tcccttcctt tttcttttca cagataacca gcccgagtca tgcagtcttt start E3/SHE505 
tcgagaaagg tgtggtttcc atggcaaaca acagaactac cagcagacct cgcaggaaac 
atcacgccta gagaattaca ggcagccgag tcaggccggg ctaagctgcg accggcagcg 
gctgctcgcc aaggactatt ataacccgca gccttacccg agctatgagg gtggcgctgg 
cacgccctct ggcactgcag ccgcggtggc cgccgacaag taccaccgag gcagcaaggc 
cctgcccaca cagcaaggcc tgcaggggag gccggctttc cctggctacg gcgtccagga SNP G269C/SHE666 
cagcagcccc tacccaggcc gctatgctgg tgaggagagc cttcaggctt ggggggcccc  253del119 
acagccacca cccccacagc cgcagccact acctgcaggg gtggccaagt atgatgagaa 
cttgatgaaa aagacagcag tgccccccag caggcagtat gcagagcagg gcgcccaggt 
gccctttcgg actcactccc tgcacgtcca gcagccaccg ccgccccagc agcccctggc SNP C493A 
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ataccccaag ctccaaaggc agaagctgca gaacgacatt gcctcccctc tgcccttccc SHE325 
ccagggtacc cactttcctc agcattccca gtccttcccc acctcctcca cctactcctc SHE324 
ctctgtccag ggtggtgggc agggggcccac tcctataaga gttgcacagc accgactgcc 
cagccccatg acaggccgct gactgccagc tccagcctgg ccccggggca gcgggtccag SHE507F 
aatcttcatg cctaccagtc gggccgcctc agctatgacc agcagcagca gcagcagcag SNP G837A 
cagcagcagc agcagcagca agcccttcag agccggcacc atgcccagga aaccctccat SHE506R/Poly# 
taccaaaacc tcgccaagta tcagcactac gggcagcaag gccagggcta ctgccagccg 
gacgcagccg tccggacccc agagcagtac taccagacct tcagccccag ctccagccac 
tcacccgccc gctccgtggg ccgctcacct tcctacagtt ccacaccgtc gccgctgatg 
ccaaacctgg agaactttcc ctacagccag cagccgctca gcaccggggc cttccccgca 1119delC 
gggatcactg accacagcca cttcatgccc ctgctcaatc cctccccaac ggatgccacc 
agctctgtgg acacccaggc tggcaactgc aagccccttc agaaggacaa gctccctgag 
aacctgctgt cggatctcag cctgcagagcc tcacggcgct gacctcacag gtggagaaca 
tctccaacac cgtccagcag ctgctgctct ccaaggctgc tgtgccgcag aagaaaggtg SHE327 
tcaagaacct cgtgtccagg accccagagc agcataaaag ccagcactgc agccccgaag SHE326/1449delC 
ggagcggcta ctcagccgag cccgcaggca caccgctgtc agagccgccg agcagcacgc 
cacagtccac gcatgcggag ccgcaggagg ccgactacct gagcggctcc gaggacccac 
tggagcgcag cttcctctac tgcaaccagg cccgtggcag ccctgccagg gtcaacagca SHE509F 
actcgaaggc caagcccgag tccgtgtcca cctgttctgt gacctctcct gacgacatgt SHE508R 
ccaccaaatc tgacgactcc ttccagagcc tacacggcag tctgccgctc gacagcttct 
ccaagttcgt ggcgggtgag cgggactgtc cgcggctgct gctcagcgcc ctggcacagg 
aggacctggc ctccgagatc ctggggctgc aggaagccat cggtgagaag gccgacaaag 
cttgggctga agcacccagc ctggtcaagg acagcagcaa gccacccttc tcgctggaga SHE329 
accacagcgc ctgcctggac tctgtggcca agagtgcgtg gccccggcct ggggagccgg SNP G1992A 
aggccctgcc cgactccttg cagctggaca agggcggcaa tgccaaggac ttcagcccag 
ggctgtttga agacccttcc gtggccttcg ctacgcctga ccccaaaaag acaactggtc 
ctctctcctt tggtaccaag cccacccttg gggttcctgc tccagacccc actacagcag SHE328 
cttttgactg tttcccggac acaaccgctg ccagctcagc ggacagcgcc aacccctttg 
cctggccaga ggaaaacctg ggggatgctt gtcccaggtg gggattgcac cctggcgagc 
ttaccaaggg cctggagcag ggtgggaagg cctcagatgg catcagcaaa ggggacaccc 
atgaggcttc ggcctgcctg ggcttccagg aggaggaccc ccctggggag aaggtggcct 
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cgttgcccgg ggacttcaag caggaggagg tgggtggggt gaaggaggag gcaggtgggc 
tgctgcagtg ccccgaggtg gccaaggctg accggtggct ggaggacagc cggcactgct 
gttccaccgc cgacttcggg gacctcccac tgctgccacc caccagcagg aaggaggacc SHE511F 
tggaagctga ggaggagtac tcctccctat gtgagctcct gggcagcccc gagcagaggc SHE510 
ctggcatgca ggacccgctg tcacccaagg ccccactcat ctgcaccaag gaggaggtgg SHE331 
aggaggtgct ggactccaag gccggctggg gctctccgtg ccacctctca ggggagtccg 2773del29/SNP G2773A 
tcatcctgct gggccctaca gtgggcaccg agtcaaaggt ccagagctgg tttgagtcct SHE330 
ctctgtcaca catgaagcca ggtgaagagg ggcctgatgg ggagcgagct ccaggggatt C2878T Non 
ccaccacctc ggacgcctct ctggcccaga agcccaacaa gcctgctgtg cccgaggcgc 
ccatcgcaaa gaaagagcct gtgccacggg gcaaaagctt acggagccgt cgggtgcacc 2966delAAGA 
gggggctgcc cgaggccgag gactccccat gcagggcacc agtgctgccc aaagacctct 
tgctccctga atcctgcaca gggccccccc agggacagat ggaaggggct ggagccccag 3103delC/3103insC 
gccggggggc ctcggaaggg ctccccagga tgtgtactcg ttctctcacg gccctgagtg SNP G3183A 
agccccgcac gcccggaccc ccaggcctga ccaccacccc tgcaccccca gacaaactgg 
ggggcaagca gcgagccgcc ttcaagtcgg gcaagcgggt ggggaagccc tcacccaagg 
ctgcctccag ccccagcaac ccggccgccc tgcctgtggc ctccgacagc agcccgatgg SNP C3357T 
gctccaagac caaggagaca gactcaccca gcacgcctgg caaggaccag cgctccatga SHE512R 
tccttcggtc acgcaccaaa acccaggaga tcttccactc caagcggcgg aggccctctg SHE513F 
agggccggct ccccaactgc cgtgccacca agaagctcct cgacaacagc cacttgcccg SHE333 
ccacattcaa ggtctccagc agcccccaga aggagggcag ggtgagccag cgggcaaggg 
tccccaaacc tggtgcaggc agcaagctct ctgaccggcc cctccatgcg ctcaaaagga SHE332 
agtcggcctt catggcgccg gtccccacca agaagcggaa cctggtcttg cggagccgca 
gcagcagcag cagcaacgcc agtggcaatg ggggagatgg gaaggaggag aggcctgagg 
gttcccccac cctcttcaag aggatgtctt ctcccaagaa agccaagccc accaagggca 3801delC 
atggcgagcc tgccacaaag ctcccacccc cggagacccc cgatgcctgc ctcaagctcg 
cctctcgggc agccttccag ggggccatga agaccaaggt gctgccaccc cggaagggcc 
ggggcctgaa gctggaagcc atcgtgcaga agatcacctc gcccagcctc aagaagttcg 
catgtaaagc gccaggggcc tctcctggta atcctctgag cccatccctt tccgacaaag SHE515F 
accgtgggct caagggtgct gggggcagcc cagtgggggt ggaagaaggc ctggtaaatg 
tgggcaccgg gcagaagctc ccaacttctg gggctgatcc gttatgcaga aatccaacca 
acagatcctt aaaaggcaaa ctcatgaaca gtaagaaact gtcttctact gactgtttca SHE514R 
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aaaccgaggc cttcacatcc ccggaggccc tgcagcctgg ggggactgcc ctggcgccta SHE335/SNP T4311C 
agaagaggag ccggaaaggc cgggcagggg cccnatggac tctccaaagg cccgctggag SHE334 
aagcggccct atcttggccc ggctctgctc ctgactcccc gagacagggc cagtggcaca 
caaggggcca gtgaggacaa ctctggtgga ggaggcaaga agccaaagat ggaggagctg SNP G4512T  
ggcctggcct cccagccccc ggagggcagg ccctgccagc cccagacaag ggcacagaaa SNP C4530T 
cagccaggcc acaccaacta cagcagctat tccaagcgga agcgcctcac tcggggccgg 
gccaagaaca ccacctcttc accctgtaag gggcgtgcca agcgacgacg acagcagcag A4685GMis/4649delC 
gtgctgcccc tggatcccgc agagcctgaa atccgcctca agtacatttc ctcttgcaag 
cggctgaggt cagacagccg gacccccgcc ttctcaccct tcgtgcgggt ggagaagcga 
gacgcgttca ccaccatatg cactgttgtc aactcccctg gagatgcgcc caagccccac 
aggaagcctt cctcctctgc ctcctcttcc tcatcctcgt cctcgttctc cttggatgca 
gccggggcct ccctggccac actccctgga ggctccatcc tgcagccgcg gccctccttg 4933delGCCG 
cccctctcct ccacgatgca cttggggcct gtggtttcca aggccctgag tacctcttgc SHE516R 
cttgtttgct gcctctgcca aaacccggcc aacttcaagg accttgggga cctctgtggg 
ccctactacc ctgaacactg cctccccaaa aagaagccaa aactcaagga gaaggtgcgg SHE339/SHE667 
ccagaaggca cctgtgagga ggcctcgctg ccgcttgaga gaacactcaa aggtcccgag SHE336 
SNP-A5175C/A5178T 
tgtgcagctg ccgccactgc cgggaagccc cccaggcctg acggcccagc tgacccggcc 5265delC 
aagcagggcc cactgcgcac cagtgcccgg ggcctgtccc ggaggctgca gagctgctac SNP G5334A 
tgctgtgatg gccgggagga tgggggcgag gaggcagccc cagccgacaa gggtcgcaaa 
catgagtgca gcaaggaggc tccggcagag cccggcgggg aggcccaggag cactgggtgc G5423A Mis 
atgaggcctg tgccgtgtgg accggcggcg tctacctggt ggccgggaag ctctttgggc 
tgcaggaggc catgaaggtg gccgtggaca tggtaagagg ccagcccagc cagggtgggg end E3 
agtgtggggt tccaaaggac aggcaggcag gcagtcgggg agccccttgt ttctagtgct 
acagtgtggg ccaaatgtgt ctgcagtctc gggacaatct gcagagtcct gagcctctct 
ggggtgtgtg ggggaagtgg aggcacccat ctggctaagg caggtcacac tcacctaccc SHE669 
tgtcccagga gacttcccgc cggggcccgt atgcccagcc accgccactc tcccactcac 
ctggcatctt caggctccag ccccacccag aatccactgg gcccctcccc atgctgtcac 
cggagatgcc aaggcccaga gaacacgagg actcccaaga ttgaacatca gggctgcccc 
gggcggtgca agagcaagtt gcccaccctc tgttcctgtc tccattgcct ctgggatgaa SHE340/SHE668 
gctaagggct caggaagacc ctctctggcg acacaggctt ggtgcatgga cccagtcaca 
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gggttcctcc ctctgcagga cagtccatgg ggtcacacag tcacaacagg cagggcgggg 
cagatccaga ccctctcacc attggctctg agaccagctt tggaagccat agtcactgag 
 
 
Exon 4 
 
gagtagctgg gactacaggc acacaccacc aaccctcact attttttgta gagacagttt 
caccatgttg cccaggctgg tatcaaactc ctggactcag gcgatcctcc caccttggcc 
tcccagagtg ctgggattac aggcatgagc cactgcacct ggcctaccag cctgtaaagc SHE527/674 
ttgagggctg ggctccaact ggagactcac ctgcctttcc tttctcttca tcagatgtgt E4 
tccagctgcc aagaagccgg ggccaccatt gggtgctgcc acaaaggatg cctccacacc SNP T5601C 
taccactacc cgtgtgccag cgatgcaggt acgagcccgc ccaggaacag gagggcattg E4 
gagcccatcc aagcagtcca gggggaccct ccctgggcac agctccccaa acccaggccc 
catctcactc ttcagtttcc ctcctctctt gccccagcaa ttcttttatc cttctgtctg 
cctagacctc tgctgggcaa tgccagggac atggaaatga ggcattcccc aggcacctgc SHE528/675 
 
Exon 5 
caagacaaga tcacacaggc cagtctctta ggaggcagtg acaagtgtgg ctggcagagt 
aaggcgggag ggagggaggg actgagggac tgcctcaagt gaggaggggc ggcacgtgga 
actcaggggg aaaagctctc cgcggaggag gtgaggtgag tcaagactgc caggccaggg 
gccgcacccg cgccgtggag tggagtggag tgtggagggt tttgtgcaga atctgattaa RA46 
ctctttgaaa agagcccctg cagtctggag cctcgcgggc agtgcggctc ccctcctggc 
tgcagacaaa accccacagc tgtggggccc ccaccctgtc ctaaccaccg aaacttctct 
ttggtcacag gttgcatatt catcgaagag aacttttctt tgaaatgtcc caaacataag E5 
gtaggggacc acagtgtttt gtagggcgag gggtgtcaag cgggagagga gccccacctc RA45 
gcacctcctt cacagtcccc tgggccccct tggctgcgca gccccgcagg gcccagccct 
aggggaggga gctctccccg cccaccccca ggagcccccg ccgccgtcca gctcaggtcc 
ctgtccactt gcgcgccgcc gccgccgaaa acccgcaggc gtcggggcat gggcagccag 
gggctggagg gcgtccctgg gacggcctcc ctgcagctcc ccaagatagg tgacagagtg 
gggcaggcgg gggcgcggga cggtggcacg gagctgaagg cgaaggtgaa ggtgaagctg 
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Exon 6 and some 3'UTR 
 
gcggagaccc cagccgcgct ctggggtcgc ctgggtctgg ggcttaggcg gggggcccac 
actgggggcg gggcctatgg actgtgaagt ccgaggtcgt cggtaactgg cgggcgggcgSHE345/C(5710-49)T 
tcttttgcag aggctgccgt agtaatccac cccaacggcc ggaggagccg ccggagcccg E6 
cctgcccgcc cgccgccgaa ggagaggagc cgcctgcgca gcccccgggc ctttgagctg UTR 
ctcccagcgc tggtccagag ccgatccttg atccgggtcc cggatcgtgg atccggccgc 
ctagggctca gacttgcggc cccgggttgg gaggaaaacc cgttccggag ccgcctgctc 
ccggaaccgg acggcacagg gcgttcttgc ccaccccagg ggccaggctt gcggaggggg SHE664 
agcccgcgga gcggccagac tccccggggc gctcagcctc cggcgagggt gggagacggc 
tttgtcctgg ggacactttc cctctggaat ctcaagacga cgtggcacac attccacgtg 
ggtgctgccg ccaccccagt cggtcgtggc gtgcagctgg gagccctggg cttgggggtg 
ggggtcgaaa cagtactgga agaggcggag ggcggctcct agctccgtgg actaggcggg 
ggagaaagga agcctttctg agagcgggct aggccggcac tggagaggcc ggagcctttg 
gaacaaaccg tgcggaacgc gtccaggggc cttcccgccc agcctttgcc agatctctcg 
tgcggttcgg gcaaagccgg ggtagacctg ggctatgctc agttaggggt tgcgggatcc UTR 
ccgagtgtgg gcgggactgg gacacccttt ggcctctgtt tgtccccttt ccagtcctcc SHE346 
accccacccc tggagcccag cctgggagcg caaaacccaa gaagcggcca gaacgcacct 
ccggctccgg cggacgcgcg accgttgtgc accaccaggg accgccgcgc ctactctgca 
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APPENDIX C 
 
 
cDNA sequence of zebrafish rai1 gene  
 
 
atgcagt ccttcagaga gcggagtggt ttccatagcg accagcactg 
ctaccagcag gaaccccaag aattaccgcg cctcgagagc tacagacatc attacagcca 
gtccagacag ggctacgagc cacacgcttt agcttctgcc gggatgtcaa cagcgggatc 
taaagactgt tacggacagc agaactatcc tgtctacacc agcgccacac agactaagaa 
accatacaga ggaggcaaaa ctccaaacca gcatctacag gcgggctaca gtaaccacat 
gggcaccgga tacacggccc agtacatgag cgaaggtcac ctgcagcaga aatgggatga 
gtcagctcag atgacccagt tcgagcagga catggtgggt cgtctggagt ctgggtcatc 
gcagtaccta gagcagaaca tgctagctat ctctcaaagt cagtgccatc tccccgccca 
gtcctccgcc ccagtctaca ccagtcccca tcagcaggga atcccaccca acccggcgcc 
atctccttta atgtacccac aaggccacat gcatttccct cagcactcgc aaacctcttc 
ttcaccttca tcggcctata tggacaaatg taatacagcg tcacatggct acaaaggcta 
tgggatacca cctaacgccc agtatggaag gcagctgagc aatcacagca gtctaaaaca 
gagtggatac agacctcaga ataattacgg ttaccagcaa actccttcga ggtctgggtt 
tgagcagggc tccctgcagg gcatgtctgg tacacaggag agccttcaga aattccagta 
ctacaatcag acccagcaaa actactgcat aactgatatt tcagtaaggt cgccggaaca 
atactaccag acctgcagtc ctagttccag tcattcaccg gcgaggtctg tggggagatc 
tccctcgtac aactccacac catcaccctt gatggcgaat gctgattcct tccagtatgg 
ccagcctccc atcaaccctg gggcttcatc atccacaggt ttgcagaatg aacaaaatat 
gctgatgccc cctcacaccc actcatcgtc cagtgtgaac cagacccaga gcttctctgg 
atcaatgaaa gaacgattct cagagaagct cctgaccaac cctagtttgt ggagtctcaa 
tgccctaact tctcaggttg aaaacatctc caacaatgtc cagcagctgc tgctgtctga 
agctctcatg gcgagcaaaa agaccagtaa acgaaaccat cctaaaaagg gagaagatta 
cagaggtcaa ctggaaggta tggatgagtc ttgtcctgaa aatcaacatg gtccttctcc 
gtctgatgct tacagcattc ccaggtccat gacagcagga ctgcaggagg gaggatactc 
cagcagcacc gaggaccaga tggaaaggaa ctattattat tttggtcagg aaaagggtca 
aggacatacc cagacacact cccgtctcag ccttgacaca gtgtccacat gctccttaaa 
ctcggctgac gatgtctccg ttaggtcagg agactcagtt cgaagtctcc agagtgtagc 
ctcggaggat aatcttaact gtgaccccag agtacaaagg gcactgtctg aagaggagcc 
cgatagctct ctctgctgca ttagagatga gaggtctccc atcggcgtaa cagctccaag 
tcctatgaaa caagagagtg attcaccacc agacataaaa cgttcagaga gcactcaaaa 
ggagaacttt gaggagtcag catggaccga gaggatggct gatgaggaca aaaccgaaca 
aagcaagccg tctgctgagc atgattgcaa aggagaggtc actgaaaaac aagagaagtg 
gctggaggat gagaaaggtc ctgctctttt tcagaaaata aataaaaccg tgctggagga 
aggttactcc tatgaaacgg aagagaatat ctaccaaggg ctacaaaaca aatatgattc 
ggagaaagaa aacacgacgg agatagactg ctttgctgaa ctcaatcaca aatgtgacga 
agacacagag ataaagacag agcattttaa atcagagcca caaaccagtg ttgaaatgcc 
aacggaagac tctcccagca attcagccac tgaactgtgt ttgccagaga aagaagaaca 
ctcaagcagt gagaattcgg tagagacccc aacatgcacc cttgagggac ctgcggacac 
ccttgaggag cagacttctg tcctctctca tacgtccact gaggtaggag atgaaaagga 
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ttcaattctg acaagctcag aggaggtcat caataataaa acagagtcac aggagtcttt 
tccagacgtc tgtggcacat atgaggaggc ggaaaacatg caacaagtaa acacagaaac 
tgcagaaagc attgcccagg acacaccaca cagagacagc gaaaggaggt cagtcatatg 
tgacattgca cctcagactc acactgccaa gagtgacttc tcagctctca atgagaaaac 
aacacctttg gctcaggcaa gggatcatca catcgattgt agtgatgcaa aggtgctgga 
gcctgactct cctcagttgc caggcaagtc gatactgcac tctgcaccat cttgggctga 
cactccaccc tctcccaaga aagcggacga ggatatggag ccaggaataa actgtcccag 
tgcagtgact ccctcagcca aaccagaggc ttttacgcca tcttcacata caagaatgtt 
cggtaagaaa catgtacggg gcaggaggag accaatgagc tcaactgcag gaataagaag 
gcagctaagt atagaaggag acactcaaac tcccaatata ccttcaagca aaaccaccga 
tattgtcgat cagatggaaa ctgcccatca gaatgttagt agtcaaacac caaaacttgt 
tacagagagt ttaccatcac ggatgtgcac tcgctcctac ggttcacaag gtagcccaaa 
ggtctcccct caagacagaa ggaaaccagg tgcaaaacct gctccaaaac caagctcaaa 
aatagctgtc aagccaggtc caaaatcaaa tccaaaacct gcaccaaagc atagtccaaa 
atcaattaca aaacctggtt caaaatcagt tcctaaatcc gaggtcatgc ctagtgtaaa 
acctggcccc aagccaggtt taaaatccac agggtccaaa gaaagtccaa agccttgtcc 
taaatctggc ccaaaatctg ccactaaatc tggtccaaaa actgcttcta aacccgcctc 
aaagcctggg tcagtaccag gagagatact tgctccaaag tcaaatcaaa acacagcaga 
gtcaaagcca attgtggcat cagtagctaa aggccccggt cgaccgaaag gaatcagtaa 
gaacaaacag atgaagatga aacaagatga aaatgttcaa acaactacag aacataccaa 
ggacacacac tgtactcaag aacttaattt gcaagatgtg accacagaat tagctttgga 
cacaattgtt ggtgttgtgg ataccactaa aggtgaaacc gtggctccca ctttggagtg 
tacgctagac agcagctgct taaaatcatt agggagagag cagaagtcta tggtgttaag 
atcacggaag caaacaaaag agaaactgac tgaagaaaaa gaacaaaacg atgataaatc 
tactaagaca ccttcagcaa tggtcatgca ggatgttact gtggatcagt cgtgtaagac 
tggaccttca aatctcgaat tgcccaagca gaaggatgtc tccacagatt cacttcaaca 
gccagatgaa gaggtggttt ccaccaagag aaaatgcagt ttaccaacct cagaaaccaa 
aaagaggaag aaaggaaggc aagatgaagt gaaggcacag gattctccat tagacatagt 
ccacattcca aagggaaaga gaaagagagg acaacgtttg cttgtggaat cagtaagcac 
tactttaact actgataccc ttcccactga tgacatcagt gacgtgccat ctgtacctcc 
tcagtgtccc actaaaacca aatatttgcc tcctcggaaa ggcaggggac ttaaatatga 
ggcaatggtt cagaaaataa catccccagg gtccaaaaag caacctgtaa gtaaccaagc 
agacattgca ctagaagaat ccacgttaaa accagtgccg caggtaccag atcaaaagga 
gacaacgaac gcccctgaga tgcctcagaa ggagggcgaa agcacaatca gtacacaaga 
acccgaaaac acagaaattc aaactccaag gaagaaaagg agaaagtggg ccactgtgga 
gagcagcgat gctccagatg taagcctgga tggtggaagt ctgattatca acacaccgag 
actagctaaa cagagagcca ttaaaaacaa ccacgagatg catctgaagc agcgaaagaa 
gagaagaaaa ggcactgaac ctcaagaaaa catccccata gtggagcaac cggagtctac 
acagaccgaa gtcttgccta catctccacc tccgccagaa actcttgaac agacagagtg 
caaggagcca ccaaatgaag tatgcgtacc actaatgaaa cccaaacgcg gcaggcggcc 
atcacttaaa aagaaacaag aggaactctc gaagagtcaa aaagaagacg aaaacgcaat 
cgagaagaaa aaaaagactg ggcccaaaaa aaagtgtgtg gatgccgtta aagttgtggt 
gaagagacct aagatcaaga caaatgaact gtctccaaca gtacaaggga cattatcaga 
cttgcgccca gatctaagtg acggaaaatc ctctgtcaga ccatacgtac acatcgacag 
ctctatggac gtcgcatctt catgcactat cgtcaacagg cccgaagaag agcagatgct 
cgctcaggct aggacaaaga gtgtacctaa tatcaaaaat caagctgcaa agacagggtc 
caactcttca gtaatgctcc agggcccctt agttaacaaa agcctatctg acagatgtct 
aacgtgctgt ttatgtggaa agccagctaa ttacagagag ctcggggact tgtgtggccc 
ctattatcct gaggactgca taccacgaaa aacgctgtca ttaacacaca ggagtgaatt 
caggcaaaac agcaactgtg ccaacgagac ggagagtagt agcattgtga aaaacacaca 
gagtgtgtgt gaggaggcca tccatcagga aaaggcaaac gaagggcact ccaggaggag 
caaaagagca attcgggaac tgtcgagaac caggcccagt tcgcgaatga ggtttaaaag 
gctgctgatt ttgcagagca gacttagtgg agcgtctccc cctgctggtg tggagggcat 
tgaaacaagt ctgcagagat tacagatgga ggccgaggaa aaagagcact gggctcatga 
   
110 
 
agcgtgtgct gtctggacca ctggcatagt cctggtggcg gataaactct ttggactgac 
cgaggctgtt cagaaagctg cacatgcaaa atgctccgga tgccaaggtg aaggagcctc 
ggtctgctgc ggctggaaga gctgtactca aagctaccat tatatctgcg ccaaagagtc 
gggctgcacg tttgaagaag aaaccttctc tattcggtgt ccgaaacaca aggtaagtgt  
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IRB protocol used 
 
Institutional review board (IRB) protocol for the SMS study 
 
2004-present – Protocol number  3784, ―Molecular analysis of Smith-Magenis 
syndrome.‖ 
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